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The absence epilepsy typical electroencephalographic pattern of sharp spikes and slow waves (SWDs) is considered to be due to
an interaction of an initiation site in the cortex and a resonant circuit in the thalamus. The hyperpolarization-activated cyclic
nucleotide-gated cationic Ih pacemaker channels (HCN) play an important role in the enhanced cortical excitability. The role
of thalamic HCN in SWD occurrence is less clear. Absence epilepsy in the WAG/Rij strain is accompanied by deficiency of the
activity of dopaminergic system, which weakens the formation of an emotional positive state, causes depression-like symptoms,
and counteracts learning and memory processes. It also enhances GABAA receptor activity in the striatum, globus pallidus, and
reticular thalamic nucleus, causing a rise of SWD activity in the cortico-thalamo-cortical networks. One of the reasons for the
occurrence of absences is that several genes coding of GABAA receptors are mutated. The question arises: what the role of DA
receptors is. Two mechanisms that cause an infringement of the function of DA receptors in this genetic absence epilepsy model
are proposed.
1. Introduction
Absence seizures, typical for many different patients with
absence epilepsy, principally differ from convulsive seizures.
To illustrate, a number of widely used and efficient anticon-
vulsant drugs enhance absence seizures in patients and in the
genetic absence models and ethosuximide is only effective
in suppressing absence seizures and completely ineffective
in other types of seizures [1–3]. Absence epilepsy is charac-
terized by the occurrence of spontaneous occurring spike-
wave discharges (SWDs) and periods of reduced alertness or
responsiveness. The SWDs are induced by hyperpolarization
and they appear on an otherwise normal EEG. The spike of
the SWD represents an excitatory postsynaptic potential and
bursts of action potentials (Figure 1(b)) of thalamocortical
and corticothalamic cells, the wave a slow wave in the EEG,
is the subsequent inhibitory phase [4, 5]. The generalized
and widespread bilaterally synchronous SWDs are the result
of highly synchronized oscillations in corticothalamocor-
tical networks. SWDs, as can be found in WAG/Rij rats,
have a local cortical origin in the perioral region of the
somatosensory cortex [6–12], which is now confirmed in
GAERS [13, 14], another well validated and often used strain
of rats with absence epilepsy [15, 16]. Local injections in the
perioral region of the somatosensory cortex of the T-type
Ca2+ channel blocker ethosuximide was rather effective in
suppressing SWDs [17], but also in Long-Evans rats with
SWDs, and inWistar rats treated with a low dose of PTZ [18].
The cortex is part of a network in which the reticular thalamic
nucleus (RTN) is an essential part. The RTN is responsible
for the initiation of sleep spindles not only in rats, but also
in other species [19, 20]. It needs to be acknowledged that
previously the RTN was considered as the pacemaker for
SWDs as well [21, 22]. Nowadays the origin of the initiation
site of SWDs is the subject of quite some research efforts,
in rats as well as in humans and it is widely assumed that
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Figure 1: The schematic representation of two types of epileptic
discharges. (a) The gradual increase in potential reaches the thresh-
old level followed by the generation of epileptic discharges. This is
typical for the EEGhallmarks accompanying convulsive seizures. (b)
The spike-wave discharge. It consists of an inhibitory phase and an
action potential. The inhibitory phase (1) appears as a slow wave on
the EEG, excitation (a series of action potentials) of the cells appears
as a spike (2). A rebound peak appears at the end of this phase and
the cycle repeats itself many times.The discharge possesses the same
profile as spike-wave discharges (with permission from Springer;
[30]).
the cortex contains a focal hyperexcitable region in which
SWDs have their origin, although the initiation site and
the number of foci might be different among patients and
between humans and rats [10, 14, 23–29].
The genetic rodent models are most widely used as
models of absence epilepsy. They allow the investigation of
the neurobiological underpinning of this type of epilepsy
and the accompanying SWDs [9, 16, 31–36]. The mice
have often spontaneous mutations such as in lethargic and
tottering mice and transgenic and gene replacement models
are also often used (for review see [35, 36]). These mice have
spontaneous epileptic seizures of which the behavioral and
electrographic features and anticonvulsant sensitivity might
sometimes be similar to those of human absence seizures
[2]. Acutely induced absence seizures can also be studied
in acute pharmacological models, 𝛾-hydroxybutyrate (GHB),
penicillin but most often a low dose of pentylenetetrazole
(PTZ) is used [37]. There are two pharmacological models
for atypical absence epilepsy. These are the AY-9944 [38, 39]
and the methylazoxymethanol acetate (MAM)-AY-9944 [40]
models in rats. Administration of the 7-dehydrocholesterol
reductase inhibitor, AY9944, early in life to either rats ormice
results in the spontaneous recurrent occurrence of atypical
absence seizures which last throughout the animal’s lifetime.
TheMAM-AY9944 model is a double hit model of medically
refractory atypical absence epilepsy since cortical dysplasias
are first induced in rat by prenatal administration of MAM
and then AY9944 is administered during the first 3 weeks
postnatally [41].
The WAG/Rij model is one of the well documented
models [9, 10, 16, 34, 42]. The SWDs of WAG/Rij rats start
to appear in the EEG when the rats are about 2-3 months. At
the age of six months, all rats of this fully inbred strain have
several hundred SWDs per day.Themodel has some features,
which further increase the interest.
(i) WAG/Rij have a changed expression of genes coding
for the low threshold T-type Ca2+ channel (𝐼Ca,T)
compared to ACI control rats [43] and absence
epileptic patients have a mutation of genes coding for
𝐼Ca,T [44–46].
(ii) Reduction of expression of the 𝛼3 subunit protein in
GABAA receptors in the RTN [47] of WAG/Rij rats
and mutation of genes coding for subunits of GABAA
receptors in people with absence epilepsy were found
[48, 49].
(iii) WAG/Rij rats have complex phenotype: they are
comorbid for depression [50–52].
We assume that the 𝐼h pacemaker channels localized in
the somatosensory cortex contribute to the initiation of the
occurrence of SWDs and that a second set of pacemaker
channels can be found in the thalamus. The latter is respon-
sible for the occurrence of thalamic delta activity and sleep
spindles, as can be assumed from the classical studies of
the firing pattern in thalamic relay cells, tonic and burst
firing modes [53, 54]. A small portion of thalamic relay cells
show bursting during SWDs, in which 𝐼h might also play
a role. The thalamus, a recipient of many cortical efferents,
is also part of a resonant circuitry for SWDs that can be
activated by the somatosensory cortex. In this way, the RTN
and its widespread connections to other thalamic nuclei form
a pathway in the propagation of cortically triggered SWDs
and sustain oscillations.
2. Hyperpolarization-Activated 𝐼h Pacemaker
Channel in the Mammalian Brain
The pacemaker channels in the mammalian brain are named
𝐼h channels, the pacemaker channels in other tissue are
named 𝐼f [30, 55]. Both are cationic pacemaker channels.
2.1. The Features of 𝐼f and 𝐼h Pacemaker Channels. Hyper-
polarization-activated cyclic nucleotide-gated cationic 𝐼f or
𝐼h pacemaker channels maintain spontaneous periodic acti-
vation, and they were discovered in heart (𝐼f) and brain
(𝐼h). Four isoforms of this channel are known (HCN1–
HCN4, hyperpolarization-activated and cyclic nucleotide-
gated) [56–61]. HCN channels resemble voltage-dependent
K+ channels; they are tetrameric and consist of monomeric
subunits, each of which contains six transmembrane domains
(S1–S6) with a P-loop (Figure 2) between the S5 and S6
domains [60, 62]. Four HCN1 subunits join and form a
HCN1 homotetrameric channel, four HCN2 subunits form a
HCN2 homotetrameric channel, and so forth. Different HCN
subunits may also join to form a heteromultimeric complex,
this substantially increases the diversity of 𝐼f, or 𝐼h channels
[62–64].
The primary analysis of the HCN channel sequence [56–
58, 60, 62] indicated the presence of five endogenous cysteine
residues in the transmembrane domains. Three of these are
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Figure 2: Probable transmembrane topology of HCN channels. Six transmembrane domains (S1–S6) of monomeric of the HCN1 subunit are
presented. Five endogenous cysteine residues are localized in transmembrane domains of all four isoforms of HCN channels. Three of them
in the 303, 318, and 347 position (Cys303, Cys318, and Cys347) are localized closer to the extracellular space, whereas the two remaining ones
(Cys298 and Cys374) are probably closer to the cytoplasmic or inner side. The cyclic nucleotide-binding domain (CNBD) is localized on the
C-terminus.The glycine-tyrosine-glycine amino-acid sequence forms a channel pore between the S5 and S6 domains (with permission from
Springer, [30]).
localized closer to the extracellular side, the Cys303 residue
in the S5 transmembrane domain, the Cys318 residue in the
aminoacid chain connecting S5 and S6, and Cys347, which
is in direct proximity to the glycine-tyrosine-glycine (GYG)
sequence that forms the channel pore. Two other cysteine
residues are localized closer to the cytoplasmic, or inner, side
(Cys298 in S5 and Cys374 in S6) (Figure 2). It is known that
cysteine has a hydrosulphate group and its reduced form
may easily participate in chemical reactions, like alkylation,
acylation, and arylation, or even cross-inking with another
nearby cysteine to form a disulphide bridge [65, 66]. These
chemical reactions are essential for association of subunits
and channel formation.
The HCN channel is open at an average membrane
potential of −80mV [67]. However, different subunits of
the HCN channel possess different functional properties. To
illustrate, HCN1 and HCN2 subunit isoforms, coexpressed in
the cerebral cortex and hippocampus, are substantially dif-
ferent in their biophysical features. HCN1 channels become
five to ten times faster activated than HCN2 channels. Also,
HCN1 channels become activated at a membrane potential
that is 20mV more positive than the potential required for
HCN2 activation [68, 69]. The HCN2 channel demonstrates
a clear response (+17mV) to cAMP binding at the cyclic
nucleotide binding domain (CNBD) on the C-terminus, the
HCN1 channel demonstrates a minimal response to cAMP
(+4mV). Therefore it can be safely assumed that HCN1 and
HCN2 perform quite different functions in the brain regions
where they predominate [70]. Heteromultimeric channels
with new properties can be found throughout the central
nervous system [68, 69]. Coexpression of HCN1 and HCN2
with heteromultimeric channel formation leads to 𝐼h cur-
rents, which are kinetically activated via a voltage-dependent
mechanism and tend to possess functional properties that are
intermediate between HCN1 and HCN2 homomeric chan-
nels. Coexpressed heteromultimeric channels demonstrate a
relatively larger shift in response to cAMP (+14mV) than
the monomeric HCN1 channel. Neither the kinetic curve
nor dose-effect curve in response to cAMP of coexpressed
heteromultimeric 𝐼h channels are a linear summation of the
independent populations of HCN1 and HCN2 homomeric
channels. These heteromeric channels have unique and new
properties [63].
Several chimers of HCN1 and HCN2 homomeric chan-
nels have been created with a modified NH
2
terminus,
transmembrane domain, and different areas of the COOH
terminus. CNBD exchange betweenHCN1 andHCN2 results
in only a small influence on the main gating mechanism,
and exerts a relatively poor effect on cAMP modulation. The
difference in the cAMPmodulatory effect depends instead on
the interaction between CNBD and the aminoacid sequence
(80 amino acids) that connects the last transmembrane
domain (S6) and CNBD.
The glycine-tyrosine-glycine (GYG) sequence found
between the S5 and S6 domains forms the channel pore
(Figure 2). The pore is formed by this aminoacid sequence
originating from all four subunits when they are united in
the tetrameric channel.The same amino acid sequence forms
a pore in many K+ selective channels [62]. The pore of the
HCN channel is permeable not only for K+ but also for Na+
ions.
2.2. 𝐼h Channels and Absence Epilepsy. The main diagnostic
sign of absence epilepsy is the presence of SWDs in human
or animal electroencephalogram (EEG). The similarity in
morphology of SWDs [32, 71] and discharges generated
by 𝐼h channel (Figure 1(b)) suggests that the 𝐼h channel is
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a contributing factor to themorphology of the spike andwave
complex. Several other authors have already hypothesized
that this nonselective 𝐼h channel plays also a crucial role in the
age-dependent development in the occurrence in SWDs [70,
72–76]. Considering that different subtypes are differently
present in cortex and thalamus, HCN1 is expressed selec-
tively in specific brain regions, among others the neocortex
and certainly on the large pyramidal neurons [58, 77, 78],
while HCN2 is more widely expressed throughout the brain,
including the thalamus; these different parts will be discussed
separately.
2.2.1. 𝐼h in Cortex. Studies aimed at elucidating the role
of 𝐼h channel activity in absence epilepsy compared 𝐼h
channels in cortical neurons of epileptic and control strains
of rats: WAG/Rij, Wistar (of the same genetic background
as WAG/Rij but less prone to absence epilepsy) and ACI
rats (an inbred strain practically devoid of epileptic activity)
[73, 79, 80].The cortex was targeted since it contains the focal
onset zone of SWDs. Patch-clamp recording from the whole
cell of the second-third cortical layer of pyramidal neurons
was supplemented by immunohistochemical, Western blot,
and PCR studies of HCN1–HCN4 subunits of the 𝐼h channel.
The fast component of 𝐼h activation in neurons of WAG/Rij
rats was significantly reduced (a 50% decrease in the current
density) and was four time slower than in the neurons of
nonepileptic Wistar or ACI rats. The results of Western blot
and PCR analysis corresponded to a decreased 𝐼h current.
A decrease by 34% was found in the level of the HCN1
subunit protein in the cerebral cortex of WAG/Rij rats
as compared to Wistar rats, but HCN1 mRNA expression
was not different. The protein and mRNA levels of the
other three 𝐼h channel subunits (HCN2–HCN4) were not
altered [73]. This loss of neocortical HCN1 function may
contribute to an increased cortical excitability since there
are substantially fewer HCN1 subunits in the combined
complex of the 𝐼h channel in the cortical zone containing the
focal region in WAG/Rij strain compared to the two control
strains.
A loss of HCN1 was also found during ontogeny: it
occurs primarily in the apical dendrites of layer 5 pyramidal
neurons in the cortex, leading to a spatially uniform 2-fold
reduction in dendritic HCN current throughout the entire
somatodendritic axis [76]. Dual whole-cell recordings from
the soma and apical dendrites demonstrate that loss of HCN1
increases somatodendritic coupling and significantly reduces
the frequency threshold for generation of dendritic Ca2+
spikes by back propagating action potentials. As a result of
increased dendritic Ca2+ electrogenesis, a large population
of WAG/Rij layer 5 neurons showed intrinsic high-frequency
burst firing. Using morphologically realistic models of layer
5 pyramidal neurons from control Wistar and WAG/Rij
animals, it was shown that the experimentally observed loss
of dendritic 𝐼h recruits dendritic Ca
2+ channels to amplify
action potential-triggered dendritic Ca2+ spikes and increase
burst firing. Thus, loss of function of dendritic HCN1 chan-
nels in layer 5 pyramidal neurons provides a somatodendritic
mechanism for increasing the synchronization of cortical
output, and is therefore likely to play an important role in the
generation of SWDs accompanying absence seizures [76].
It has been shown that neonatal handling and maternal
deprivation postnatally (1–21 days) resulted in reduced num-
ber of absences, decreased interspike interval, and changes in
power of the frequency spectrum of SWDs in adult WAG/Rij
rats [81]. Whole cell patch-clamp recordings from the cells of
the fifth pyramidal layer, in situ hybridization, and Western
blot analysis of the cortex of adult WAG/Rij rats [74] showed
an increase in the HCN1 protein level in the somatosensory
cortex of handled and mother-deprived rats as compared
to control rats. This increase was selective for the HCN1
subunit and did not affect the expression of HCN2–HCN4
subunit proteins; neither did expression of the mRNA of any
subunit (HCN2, HCN3, and HCN4). These results indicate
that relatively mild changes in the environment of neonatal
rats have long-lasting consequences for the occurrence of
paroxysmal activity later in life and suggest that increased
concentration or better, an increased proportion of HCN1
subunits in 𝐼h channel composition in a small area of
the somatosensory cortex is related to a reduction in the
number of SWDs. An increased number of HCN1 subunits
in the channel due to their extensive expression (increased
HCN1 protein level without changes in HCN2, HCN3, and
HCN4 mRNA levels), and consequently, a decreased num-
ber of HCN2, HCN3, and HCN4 subunits in the channel
complex, as mentioned above [68, 69], result in impaired
activity of the 𝐼h channel, reduced cortical excitability, and
less SWDs, as it has been demonstrated experimentally
[73, 74, 81].
Besides the age-dependent decrease in the number of
HCN1 subunits and in protein expression in the deep layers
of the focal region [76], a chronic drug treatment aimed
at antiepileptogenesis in the same model confirmed that
the reduction of SWDs was accompanied by an increase in
HCN1, producing levels that resemble nonepileptic controls
[82]. In addition, neonatal manipulations [74] increased the
number of HCN1 subunits and decreased SWDs, providing
evidence for the negative correlation between SWDs on the
one side and this 𝐼h channel otherwise.
Blocking the 𝐼h channels of Layer V neurons by ZD7288
(4-ethylphenylamino-1,2-dimethyl-6-methyl-aminopyrimid-
inium chloride), as well as a loss of HCN1 subunits, increases
somatodendritic coupling, increases Ca2+ conductance by
reducing the frequency threshold for induction of dendritic
Ca2+ electrogenesis, increasing synchronization of cortical
output and burst firing [76]. Therefore, ZD7288 when
administered in the cortex can enhance SWDs. It is, however,
possible that this property of 𝐼h channels is only present in
neurons of the the subgranular layers, since 𝐼h channels of
thalamic neurons have different biophysical properties.
It can be concluded that an age-dependent loss of neo-
cortical HCN1 function contributes to an increased cortical
excitability in the form of more and longer spontaneous
occurring SWDs and that various early manipulations,
such as maternal deprivation but also treatments aiming at
antiepileptogenesis confirm the negative relation between
HCN1 and SWDs.
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2.2.2. 𝐼h in Thalamus: Its Role in Delta, Sleep Spindles, and
SWDs. The in vitro studies done in the late eighties and
in the nineties of the last century were influential for the
ideas than have been developed on the role of the interaction
between 𝐼h and 𝐼Ca,T [83]. Basically, the interaction of 𝐼h
and 𝐼Ca,T channels has been assumed to be the basis for
burst firing in thalamocortical (TC) cells [84]. Briefly, upon
hyperpolarization of the TC cell membrane by a reduction of
depolarizing inputs beneath the resting membrane potential,
𝐼h is activated and produces a slow pacemaker depolarization
until the threshold voltage of activation of 𝐼t is reached.
The hyperpolarization concomitantly deinactivated 𝐼t and
the pacemaker depolarization subsequently activates 𝐼t that
leads to the generation of a low-threshold Ca2+ potential,
bringing the membrane potential positive to firing threshold.
This evokes high-frequency burst of action potentials. The
transient nature of 𝐼t will then terminate the depolarization
and hyperpolarize the cell. Less 𝐼h (less inward current) than
at the beginning of the Ca2+ spike will be activated because
𝐼h partly deactivated during the depolarization associated
with the Ca2+ potential. As a consequence, the membrane
potential will hyperpolarize to a potential more negative than
the 𝐼t activation threshold.The cell will thus reach the peak of
the hyperpolarization and reactivate 𝐼h, restarting the cycle.
Thus, while 𝐼t is responsible for the large-amplitude depolar-
izations, 𝐼h mediates both the slow pacemaker depolarization
necessary to activate 𝐼t and the hyperpolarization that follows
low-threshold Ca2+ potentials [85]. The burst firing mode is
activated during drowsiness, with TC and CT cells undergo-
ing a progressive hyperpolarization from drowsiness and the
early stages of sleep to the late sleep stage of deep slow wave
sleep. The frequency of the burst firing mode is determined
by the amount of hyperpolarization, such that sleep spindle
oscillations (7–12Hz) occur at more depolarized membrane
potentials than delta oscillations [86]. It has been assumed
based on in vitro studies that this thalamic burst firing mode
can also be the physiological correlate of SWD. However,
studies in GAERS have demonstrated that TC relay cells were
not associated with rhythmic IPSPs, Ca2+ currents, or burst
discharges, but only with the occasional firing of a single
action potential [87, 88], and that during SWDs a minor
portion of TCR cells (7% inGAERS, [87]) showCa2+ currents
and burst discharges. The bursting of such a small portion
of TCR cells appears to be sufficient for the sustainment of
SWDs. In agreement with this finding is that local injections
of the low-threshold Ca2+ blocker ethosuximide are not very
active when injected in the thalamus [17]. Moreover, there are
no in vivo studies in genetic models which investigated the
role of thalamic 𝐼h.
However, burst firing inTCcells is crucial for the presence
of delta waves. In in vitro rat, cat, and ferret studies, isolation
of TC relay cells from synaptic input from CT and RTN
leads to a hyperpolarization of the cells and onset of self-
sustained oscillations in the delta (0.5–4Hz) frequency band
[85, 89, 90]. Likewise hyperpolarization of TC neurons by
means of hyperpolarizing current injection leads to burst
firing of the neurons also in the delta frequencies [85], and
this goes together with the activation of 𝐼h [85, 89]. In vivo
studies which confirmed this were, however, not done.
Studies on the role of 𝐼h in spindle oscillations have
been performed in thalamic slices with neurons that either
show spontaneous spindling, such as in the ferret LGNd
[91], or where thalamic spindle activity is evoked by applying
hyperpolarizing current pulses mimicking IPSPs arriving
during spindle waves in the intact RTN/PGN-TC network
[92]. Induced spindle activity in TC neurons has been shown
to go together with 𝐼h activation, lending evidence for an
involvement of 𝐼h in spindle generation [93, 94]. Further
evidence for a role of 𝐼h in spindle oscillations comes from
𝐼h manipulation studies in thalamic slices. Intracellular injec-
tion of depolarizing current into spindling LGNd neurons
resulted in inactivation of 𝐼t, abolition of rebound Ca
2+
spikes and cessation of the spindle oscillations [95]. The type
of burst firing oscillation (delta and spindle oscillations) is
determined by themembrane potential [86], that is on its turn
set by 𝐼h [70, 93]. 𝐼h thus plays an important role in setting the
membrane potential that determines the type of burst firing
oscillation present in the TC cells. But different from delta
oscillations, 𝐼h and the pacemaker potential created by low-
threshold Ca2+, does not seem to be of critical importance for
spindles since blockade of 𝐼h does not lead to the cessation of
the oscillation, as seen in delta oscillations [85, 89, 96, 97],
but to a failure in spindle termination [89, 92].This questions
the exact role of 𝐼h in spindle generation; moreover in vivo
studies towards the role of 𝐼h in sleep spindle generation are
lacking as well.
It can be concluded that the interaction of 𝐼h and 𝐼t
seems critical for the generation of delta oscillations, 𝐼h seems
involved in sleep spindle generation, and however its exact
mechanisms are beyond the scope of this paper. A dominant
role for 𝐼h in thalamic bursting underlying SWD can also be
doubted since a small portion of TC cells show this behavior.
However, the possibility exists that 𝐼h and 𝐼t interact in the
portion of TC cells that do show bursting in which the 𝐼h and
𝐼t interact as a tandem.
2.2.3. 𝐼h in Thalamus: A Different Role. The role of thalamic
𝐼h was investigated in WAG/Rij rats: high HCN1 mRNA
and protein expression without alterations in HCN2–HCN4
expressionwas found in thalamic neurons [98].These authors
found also that that burst discharges in thalamocortical
neurons locked to SWDs were prolonged during blockade of
𝐼h by Cs
+ and ZD7288, similar as has been found for sleep
spindles. This was associated with hyperpolarizing shift in
𝐼h activation, a decrease in cAMP responsiveness of 𝐼h in
TC neurons and resulting impairment to shift from burst
to tonic firing, which in turn produced long burst activity
after recruitment of 𝐼h during SWDs. On the basis of these
results and shifts of 𝐼h channel reactivity induced by high
concentrations of cAMP, Budde et al. [98] hypothesized
that increased HCN1 expression in the epileptic thalamus
is associated with decreased 𝐼h channel reactivity to cAMP
in thalamic neurons and leads to a loss of control over the
channel, which, in turn, prolongs high 𝐼h channel activity
during absence seizures.
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Interesting results [75] were also obtained during the
study of the regulation of the pacemaker 𝐼h channel in
the thalamus of GAERS rats; the function of the 𝐼h chan-
nel and subunit composition in TC-neurons were studied
before (presymptomatic) and when (symptomatic) SWDs
were present in the EEG. The voltage-dependent 𝐼h current
remained unaltered in mature somatosensory neurons, both
in vivo and in vitro. However, an increase in 𝐼h current by
the phasic, practically physiologic, impulse of cAMP was
diminished by approximately 40% and the half-maximal
cAMP concentration was approximately fivefold increased.
This diminished sensitivity of 𝐼h current to its main cellular
modulator preceded the beginning of epilepsy, lasted during
its chronic phase, and accompanied the elevated expression
of mRNA of the cAMP-insensitive HCN1 subunit of the
channel (>50%) without alterations in HCN2–HCN4mRNA
expression.
Changes in excitability of TC neurons were analyzed by
measuring the delayed upregulation of the 𝐼h current. This
current was caused by Ca2+-triggered cAMP synthesis and
is essential for finishing synchronized oscillations in vitro.
Repeated recovery of the Ca2+ spike induced the normal
deceleration of upregulation of the 𝐼h current in mature
GAERS neurons, sufficient to reduce the spontaneous rhyth-
mic burst discharges. These adaptive mechanisms take place
despite cAMP turnover and involve increased intracellular
Ca2+ concentration in response to repeated low-threshold
Ca2+ discharges. Thus, HCN channels may play an ambient
role in absence epilepsy. The weakening of the binding of
cAMP to HCN channels in the thalamus proceeds, and
likely promotes, epileptogenesis in GAERS rats, whereas
compensatory mechanisms stabilizing the function of 𝐼h
channels contribute to the completion of the SWDs in chronic
absence epilepsy [75].
A quantitative model (Figure 3) describes how 𝐼h and
𝐼t cooperate and how the subcompositions of the subunits
determine the net effect (depolarization) of hyperpolarizing
inputs. It is based on Kuisle et al. [75]. The tandem consisting
of 𝐼h and 𝐼Ca,T works as follows: the hyperpolarization of the
cellmembrane opens a 𝐼h channel and themembrane is depo-
larized by an amount 𝑁. Next the hyperpolarization opens
the 𝐼Ca,T channel and Ca
2+ enters the cell, increases activity
of adenylate cyclase, and increases cAMP concentration as
the result of selective activation of PKA (cAMP-dependent
protein kinase-A) isoforms. The cAMP binds to the CNBD
domain and enhances the ion flow and amount of membrane
depolarization (gating mechanism) to a value 𝑀. The total
amount of depolarization 𝐼hDep = 𝑁 +𝑀.
When the 𝐼h channel consists of four HCN1 subunits,
as the case in the cortex for the large pyramidal cells, then
the interaction of cAMP with the CNBD HCN1 subunit
strengthens the gating mechanism and the depolarization is
increased by 4mV [63]. In this case, 4(HCN1); 𝐼hDep = 𝑁 +
(4 × 4)mV = 𝑁 + 16mV.
When cAMP interacts with CNBD of an HCN2 subunit,
as is the case in the thalamus, then the gating mechanism is
amplified and the depolarization is increased by 17mV [63].
The subunit composition can be either:
Na+ K+ Ca2+
CNBD
cAMP
𝐼h 𝐼Ca,T
Figure 3: Schematic representation of the functional interaction
between 𝐼h and 𝐼Ca,T channel, for explanation see text.
3(HCN1) + 1(HCN2); 𝐼hDep = 𝑁 + (3 × 4)mV +
(1 × 17)mV =𝑁 + 29mV
2(HCN1) + 2(HCN2); 𝐼hDep = 𝑁 + (2 × 4)mV +
(2 × 17)mV =𝑁 + 42mV
1(HCN1) + 3(HCN2); 𝐼hDep = 𝑁 + (1 × 4)mV +
(3 × 17)mV =𝑁 + 55mV
4(HCN2); 𝐼hDep =𝑁 + (4 × 17)mV =𝑁 + 68mV.
This implies that the composition of the heteromeric
𝐼h channel, as can be found for example, in the thalamus,
determines the amount of depolarization and the subsequent
activation of voltage-activated Ca2+ channels. With age, the
contribution of HCN1 subunits decreases (through a process
called trafficking) and is replaced by HCN2 subunits. It does
also explain that during aging the reaction to hyperpolarizing
inputs might increase the amount of depolarization; in other
words, during aging the thalamus will react with larger
depolarizations upon the same hyperpolarizing inputs.
Our hypothesis that burst firing in TC neurons is caused
by (tandem) hyperpolarization-activated 𝐼h channel and
hyperpolarization-activated (𝐼Ca,T) channel and that burst
firing of at least someTCcells plays a role in SWDoccurrence,
is supported by pharmacological studies indicating that
increased GABAergic inhibition in the ventral basal (VB)
complex of the thalamus, as induced by local injections of
GABA-agonists, enhances SWDs. Remember that opposite
effects (a decrease in SWDs) were obtained by injections of
GABA agonists in the focal zone of the cortex [15, 99, 100],
suggesting that here depolarization rather than hyperpolar-
ization promotes burst firing [76, 101].
The literature reviewed in this paragraph suggests that 𝐼h
and low-threshold T-type Ca2+ channels in TC cells work in
tandem in order to generate burst-like activity, the assumed
neurophysiological firing pattern that forms the basis of delta
waves, sleep spindles and perhaps SWDs. The latter remains
uncertain since the vastmajority of TC cells do not showburst
firing activity during SWDs. Hyperpolarization opens the 𝐼h
channel, and cationic current depolarizes the membrane to
the threshold and induces a Ca2+ spike. Hyperpolarization
also opens the 𝐼Ca,T channels. The entrance of Ca
2+ ions into
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the cell induces Ca2+-dependent cAMP synthesis, and cAMP
dramatically increases channel activity through binding to
the CNBD locus of HCN subunits. The HCN1 subunit
responds weakly to cAMP binding; therefore, a decrease in
the proportion of HCN1 subunits in the channel increases
pacemaker activity and an increase in the proportion of
HCN1 subunits in the channel decreases pacemaker activity.
The analysis of experimental data shows that one of the basic
mechanisms of the long-term regulation of 𝐼h pacemaker
activity is modification and consolidation of a number of
HCN1 subunits in the pacemaker channel by the help of the
transduction signal.
3. GABAergic Inhibitory System
3.1. Pharmacological Investigations. The GABAergic system
has two types of receptors. The first type of receptors mediat-
ing fast postsynaptic GABA reactions (IPSP’s) are ionotropic
GABAA receptors, including in its structure a chlorine
channel. The second type of receptors mediating slow GABA
reactions is metabotropic GABAB receptors. GABAB recep-
tors are coupled indirectly to K+ channels. When activated,
these receptors can decrease Ca2+ conductance and inhibit
cAMP production via intracellular mechanisms mediated by
G proteins. GABAB receptors can mediate both pre- and
postsynaptic inhibition. Presynaptic inhibition may occur
as a result of GABAB receptor binding on nerve terminals
causing a decrease in the influx of Ca2+, thereby reducing the
release of neurotransmitters. Postsynapticaly, the G protein-
gated inwardly rectifying K+ (GIRK) channels are activated
by stimulation of Gi/o-coupled GABAB receptors and provide
an important mechanism for the slow inhibitory modulation
of cellular excitability in the brain [102–104].
3.1.1. GABA
𝐴
Receptors. The GABAA receptors can be
allosterically facilitated (increase of chlorine current) by ben-
zodiazepines [105–107]. Pharmacological studies with spe-
cific agonists and antagonists of the benzodiazepine (BDZ)
receptor focused on the GABAA receptor complex. A series
of drugs belonging to the class of the 𝛽-carbolines were
evaluated, mainly partial agonists such as ZK 91296 and
ZK 112119 (abecarnil) and compared with the full agonist
diazepam [108–110]. Diazepam showed all behavioral and
electrophysiological changes characteristic for the BDZ, ZK
91296 reduced seizure activity without inducing signs of
sedation, sleepiness, myorelaxation, and changes in behavior
or EEG spectral content. Another member of the 𝛽-carboline
family, the partial inverse agonist FG 7142, aggravated
epileptic activity, with slightly enhanced immobile behav-
ior, suggesting anxiogenic properties. The results not only
demonstrate that the multiple effects of the BDZ could be
separated by these compounds, but also that the antiepileptic
activity is not related to changes in spectral content of the
EEG. Because of its selective activity, ZK 91296 appears to
be more suitable than diazepam in reducing seizure activity.
Finally, FG 7142 seems a genuine partial inverse agonist
which has some, but not all, of the inverse effects of a full
agonist [108]. Next the effects of the 𝛽-carboline (abecarnil,
ZK 112119) were determined in two experiments: in the first
the antiabsence profile of abecarnil was evaluated inWAG/Rij
rats. In the second experiment, effects on sleep and behavior
were investigated in nonepileptic Wistar rats. It was found
that, similarly to classical BDZ, abecarnil possessed a strong
antiepileptic character and also changed the backgroundEEG
tomore high-frequency waves and less spindle activity. It also
produced more immobile behavior. Abecarnil induced only
small, marginally significant increases in slow-wave sleep
while reducing REM sleep as a proportion of total sleep. It
also reduced the number of REMperiods.These observations
are consistent with the proposed partial agonist activity of
abecarnil, a drug with interesting therapeutic implications
[111]. Rather similar results on the antiabsence action of the
full agonists of BDZ receptors have been found in GAERS
[112], emphasizing the similarities in the pharmacological
profile of the two genetic absence models.
Hypnotic drugs are known to possess antiepileptic activ-
ity. Therefore, the effects of the BDZ hypnotic midazolam
and the imidazopyridine hypnotic Zolpidem (both 10mg/kg)
on sleep-wake states and on the number of SWDs were
evaluated in WAG/Rij rats. Both hypnotics reduced the
number and duration of SWDs.The initial decrease of SWDs
after midazolam, however, was followed by a rebound. The
antiabsence activity of zolpidem mimics that of midazolam
and is well correlatedwith the equipotent hypnotic action and
anticonvulsant effect in the isoniazid test [113].
The assumed tolerance to BDZwas investigated by inject-
ing diazepam (5mg/kg) twice daily for 23 days in WAG/Rij
rats. After this, the rats received the agonist, diazepam, or the
antagonist, flumazenil (Ro 15-1788). Acutely administered,
diazepam reduced SWDs, while flumazenil was without clear
effects. The effects were rather different after chronic admin-
istration: both compounds increased the number of SWDs
[114], suggesting that repeated administration of diazepam
abolished its antiepileptic action and even reversed its action.
Also Flumazenil produced an increase in SWDs after chronic
diazepam treatment. The antiepileptic effect of diazepam,
acutely administrated, has been found also by others in
GAERS [115].
The next allosteric facilitator of GABA inhibition at
the GABAA receptor is the group of neurosteroids [116].
They have clinical relevance partly because the ovarian
hormones acting as neurosteroids are held responsible for the
variation of seizure frequency during the menstrual cycle,
around puberty, and menopause. The variations in seizure
frequency have been attributed partly to the antiepileptic
action of progesterone: it reduces seizures during the luteal
phase.However, studies on catamenial epilepsy (derived from
the Greek word katomenios, meaning “monthly”), clusters
of seizures around specific points in the menstrual cycle,
have not always distinguished between patients with focal
and generalized seizures. Gru¨newald et al. [117] described
a patient whose absence seizures exacerbated when she
was given progesterone. This indicates that, in contrast to
the well-known anticonvulsant and antiepileptic properties
of progesterone in most animal models and in almost all
seizure types, absence epilepsy might be an exception in
the sense that progesterone increases absence seizures [118].
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The role of the sex hormones, but also of ganaxolone and
other neurosteroids, has been thoroughly investigated in the
genetic and pharmacological absence models. Ganaxolone
(3𝛼-hydroxy-3𝛽-methyl-5𝛼-pregnan-20-one) is a synthetic
neurosteroid with anticonvulsant properties in a number of
seizuremodels as well as the ability to enhance function of the
GABAA receptor complex via the neurosteroid binding site.
The effect of ganaxolone on absence seizures was assessed in
the low-dose PTZ and the GHB model. Ganaxolone resulted
in a significant prolongation of absence seizure in both
models and in doses above 20mg/kg it produced bilaterally
synchronous SWDs associated with behavioral arrest. These
data suggest that augmentation of GABAA receptor complex
function by neurosteroids has the potential to result in or
exacerbate absence seizures [119]. Systemic administration
of the neurosteroids allopregnanolone and pregnenolone
sulfate was studied inWAG/Rij rats. Allopregnanolone is also
a positive modulator of the GABAA receptor, it increased
dose dependently the number and total duration of SWDs.
Pregnenolone sulfate, also a positive modulator of NMDA
receptors, also increased those parameters, though only at the
highest dose used (100mg/kg) and only in the first hour post-
injection. The obtained data indicate that both these neuros-
teroids aggravate SWD activity. These proepileptic activities
of these neurosteroids contrasts with the anticonvulsant
effects of many of these neurosteroids and they point to a
different pharmacological profile of epilepsy with convulsive
or nonconvulsive seizures [120]. In the next experiment the
influence of endogenous neurosteroids on SWDs was inves-
tigated in femaleWAG/Rij rats in a chronic EEG study during
a complete ovarian cycle [121]. A circadian pattern emerged
for the number of SWDs: a nadir during the first hours of the
light period, and an acrophase during the first hours of the
dark period. This daily maximum was increased at proestrus
day compared with the other days of the cycle, coinciding
with an increased progesterone plasma level specifically at
these hours of this day. This clearly suggests that even shifts
in physiological concentrations of progesterone are already
large enough to enhance SWDs. The results are presented in
Figure 4.
There was no difference in the first few hours of the
light period in the number of SWDs between proestrus
and the three other days, suggesting that estradiol has no
effect on SWDs. In the second study, the effects of systemic
administration of progesterone and 17𝛽-estradiol on SWDs
and spontaneous behavior were investigated. It was con-
firmed what was found in the long term EEG study: proges-
terone increased the number and total duration of SWDs;
17𝛽-estradiol was completely ineffective. The administration
of RU 38486, an antagonist of intracellular progesterone
receptors, had no effect on SWDs and did not block the
stimulatory effect of progesterone. The intracellular estrogen
receptor antagonist tamoxifen did not evoke alterations in
the number or duration of SWDs either. The results indicate
that estradiol is not affecting SWDs and that progesterone
aggravates SWDs, but the progesterone effect is not medi-
ated through intracellular receptors. Since progesterone is
rapidly metabolized in the brain to the positive modulator
of GABAA receptor allopregnanolone, which is also known
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Figure 4: Hourly number of SWDs (mean and sem) in female
WAG/Rij rats across the ovarian cycle. Note the circadian pattern
across all four days and the increase in SWDs at the last hours of
the light and first hours of the dark period of the proestrus day. It
is at specifically these hours that progesterone levels are increased
(adapted, [121]).
to increase SWDs in WAG/Rij rats, it is rather likely that the
epileptoformic effects of progesterone are mediated through
this metabolite [121]. In order to elucidate whether the
regulatory effect of progesterone depends indeed on its
conversion to allopregnanolone, the effect of finasteride, a
5𝛼-reductase inhibitor, on progesterone-induced increase in
SWDs was studied. Progesterone dose dependently increased
the number of SWDs during the first hour after injection.
Finasteride alone had no effect on the number of SWD,
up to 24 h following its administration. Pretreatment of
rats with finasteride, however, blocked the progesterone-
induced enhancement of SWD.This indicates that the action
of progesterone is mediated by its neuroactive metabolite
allopregnanolone, through strengthening ofGABAA receptor
activity [122].
The administration of both progesterone and allopreg-
nanolone exacerbated seizures in the AY model (an atypical
absence epilepsy model) in agreement with the outcomes in
WAG/Rij rats, whereas 17𝛽-estradiol attenuated SWDs (this
ovarian hormone does not modulate absences in the typical
absence model). Neither mifepristone nor tamoxifen blocked
the effects of progesterone and 17𝛽-estradiol, respectively, on
SWDs duration in the atypical absence model, suggesting
that these two sex hormones are working in a manner inde-
pendent of their intracellular neurosteroid receptor [123].
Anyway, the differential role of estradiol in typical and
atypical absence seizures emphasizes the differences between
these types of epilepsy [41].
The effects of neurosteroids on SWDs in WAG/Rij rats
were also studied by local microinjections [99]. Allopreg-
nanolone and ganaxolone (the two positive allosteric mod-
ulators of the GABAA receptor complex acting on the steroid
recognition site) and pregnenolone sulphate, (the negative
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allostericmodulator ofGABAA receptors and a positivemod-
ulator of NMDA receptors) were investigated. Focal bilateral
microinjection of the two GABAA positive modulators into
some thalamic nuclei (nucleus ventralis posteromedialis,
NRT, nucleus ventralis posterolateralis) increased SWDs.
Both compounds reduced number and duration of SWDs
when microinjected into the perioral region of the primary
somatosensory cortex, the focal region. This demonstrates
that there is not a general increase in inhibition, instead
there seems to be an increased inhibition on the level of the
VB, not a decrease in inhibition in the RTN [15] and the
focal zone in the cortex.The effects of pregnenolone sulphate
were more complex and depended on the dose and the site
of administration: generally, at low doses in RTN and focal
cortical region an increase in number and mean duration
was found, and a reduction at high doses. The effects in the
ventralis posteromedialis and posterolateralis were a decrease
and no effect, respectively, on SWDs. It was concluded that
neurosteroids might play a role in absence epilepsies and that
their action depends on the activity in specific neuronal areas.
More specifically, the results show that a lack of inhibition
at the focal cortical site may be a cause of the increased
excitability.
Some researchers have studied the role of the GABAA
receptor site. The effects of specific GABAA receptor agonist
and antagonist, muscimol and bicuculline, respectively, were
studied by intracerebroventricular injections. EEG regis-
trations and behavioral observations showed that musci-
mol dose dependently increased the nonconvulsive absence
seizures. Besides this, it induced EEG spikes and body
twitches. Bicuculline induced spikes and body twitches as
well but decreased the nonconvulsive epilepsy. All effects
of muscimol were blocked by bicuculline and vice versa,
which suggests that the observed effects are genuine GABAA
effects [124]. The other agonists of GABAA receptors such as
4,5,6,7-tetrahydroisooxazolo(5,4-c)pyridin-3-ol (THIP), L-
baclofen [115, 125] enhanced the duration of SWDs in a dose-
dependent fashion.
All these described results implicate that nonconvulsive
epilepsy can be caused by a GABAA receptor hyperfunction,
although this is an oversimplification. In general, the opposite
action of GABAmimetic drugs points to a pharmacological
difference between convulsive and absence types of epilepsy.
The local injection studies demonstrated that there is GABAA
hyperfunction in the VB, but a GABAA hypofunction in the
focal cortical region.
3.1.2. GABAB Receptor. TheGABA𝐵 receptor antagonist CGP
35348 was intraperitoneally given in doses of 100, 300, and
900mg/kg to oldWistar rats, endowed with similar SWDs as
WAG/Rij rats and GAERS. The effects on sleep and behavior
were investigated as well. The low and middle dose of the
drug produced an increase in the duration of REM sleep,
the REM sleep latency was correspondingly reduced. Non-
REM sleep and total sleep duration increased and an s-
shaped dose-response relationship was found. Explorative
behavior was diminished. Number and duration of SWDs
were reduced after all doses of CGP 35348, confirming
the strong suppressive action of this GABAB antagonist
on absences [126]. Others have described similar effects in
GAERS [127] and in the lethargic (lh/lh) mutant mice model
[128]. Antagonists of the GABAB receptors suppressed SWDs
whereas agonists of GABAB receptors exacerbated them. Fur-
thermore, GABAB receptor binding and synaptically evoked
GABAB receptor-mediated inhibitions of NMDA responses
were selectively increased in lh/lh mice. Therefore, enhanced
GABAB receptor-mediated synaptic responses may underlie
absence seizures in the lh/lh mice, and GABAB receptor
antagonists hold promise as antiabsence drugs [128]. The
microinjections of the GABAB agonist [(−)-baclofen] and the
antagonist CGP 35348 in anterior ventral lateral thalamic
nucleus, RTN and nucleus reunions decrease and increase,
respectively, absence seizures in (lh/lh) mice [129]. Next
the antiabsence effect of the GABAB receptor antagonist
SCH 50911 was investigated in the lethargic (lh/lh) mutant
mouse and in two rat models in which absence seizures
were induced by administration of either GHB or a low-dose
(20mg/kg) PTZ. SCH 50911 abolished seizures in all three
models in a dose-dependent fashion. In each model SCH
50911 was more potent than the GABAB receptor antagonist
CGP 35348, ethosuximide, trimethadione, and valproic acid.
SCH 50911 was equipotent as the GABAB antagonist CGP
46381 in the lh/lh mouse model [130]. Further experiments
examined the effectiveness of a range of specific GABAB-
receptor agonists and antagonists of varying specificity, as
well as the specific GHB-receptor antagonist NCS 382, in
the GHB and low-dose PTZ models. All specific GABAB-
receptor antagonists as well as the specific GHB-receptor
antagonist produced blockade of absence seizures in both
models; pretreatment with GABAB receptor agonists resulted
in generalized absence status epilepticus lasting for hours.
These data confirm that specific GABAB-receptor antagonists
have antiabsence activity, that the same holds for specific
GHB-receptor antagonists, and raise the possibility that both
GHB- and GABAB-antagonist drugs have the potential to
be useful therapeutic agents in generalized absence seizures
[131].
Systemic injections of the GABAB receptor antagonists
suppress completely SWDs in GAERS [127]. In the same
strain, bilateral injections of the selective GABAB receptor
agonist R-baclofen into the specific relay nuclei and the RTN
increased SWDs dose dependently, whereas injections of a
GABAB antagonist CGP 35348 into the same sites decreased
these seizures dose dependently.
The effect of R-baclofen on SWDs could be blocked by a
subsequent injection ofCGP 35348 at the same site. Injections
of R-baclofen or CGP 35348 in the midline thalamus had
no effect. Bilateral injections of R-baclofen into the spe-
cific relay nuclei of nonepileptic rats induced synchronized
rhythmic oscillations on the cortical EEG. These results
suggest that GABAB receptors in the ventrolateral thalamus
and in the RTN are involved in an oscillatory activity
which underlies SWDs [132]. SWDs in GAERS were also
dose dependently suppressed by i.p. administration of the
GABAB receptor antagonists CGP 36742 and CGP 56999,
and by bilateral microinjections of the same compounds
into the lateral nuclei of the thalamus. In rats susceptible to
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audiogenic seizures, intraperitoneal administration of both
GABAB receptor antagonists, at doses which suppressed
absence seizures, facilitated the elicitation of sound-induced
tonic seizures. In nonepileptic control rats, intraperitoneal
injections of higher doses of CGP 36742 and CGP 56999
induced delayed clonic convulsions, which were suppressed
by pretreatment with baclofen. c-Fos protein was expressed
after GABAB receptor antagonist-induced clonic seizures in
the cortex, hippocampus, amygdala, perirhinal, and piriform
cortex. Intracortical and hippocampal microinfusion of both
GABAB receptor antagonists produced focal seizures. The
authors concluded that GABAB receptor antagonists induce
convulsions in cortical and limbic structures but suppress
nonconvulsive absence seizures by blocking thalamicGABAB
receptors [133].
Somewhat different conclusions were drawn by Staak
and Pape [22] in WAG/Rij rats: their in vivo studies in
anesthetized WAG/Rij rats in combination with single-unit
recordings and microiontophoretic techniques in the ven-
trobasal thalamic complex showed that the application of the
GABAB receptor antagonist CGP 55845A exerted a statis-
tically insignificant modulatory effect on neuronal activity
during spontaneous SWDs but significantly attenuated the
bicuculline-evoked aggravation of SWD-related firing. This
indicates that GABAA receptor-mediated events are recruited
with each SWD and that SWD-related activity can be evoked
with no significant contribution of GABAB receptors. It is
obvious that their results voted against a predominant or even
exclusive contribution of GABAB receptors to spontaneous
SWDs in thalamic relay nuclei in the WAG/Rij strain, but
rather point to a critical role of GABAA receptor activation.
Whether this difference is due to the neurolept anaesthetic is
not immediately clear.
The GABAB receptor antagonists CGP55845A and
CGP62349 suppressed the development of the absence
syndrome to a larger extent in mice than in rats with GHBL-
induced absence epilepsy in a chronic treatment protocol in
which both GHBL and the GABAB antagonists were given
for 33 days. The absence syndrome was observed after 3
weeks of treatment in the saline group. A third antagonists
CGP71982 suppressed it later than the other two antagonists
(fifth week) [134], suggesting that GABAB receptors are also
involved in epileptogenesis.
The effects of combined and single administration of
the GABAB receptor antagonist CGP 36742 and 𝛼-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) recep-
tor antagonist, 7,8-methylenedioxy-1-(4-aminophenyl)-4-
methyl-3-acetyl-4,5-dihydro-2,3-benzodiazepine (LY 300164)
on SWDs were also investigated in WAG/Rij rats in order
whether the combined treatment might yield additive effects.
CGP 36742 was effective as it reduced the number and
mean duration of SWDs dose dependently. LY 300164 had
minor effects: only the highest dose (16mg/kg) reduced
the number of SWDs in a short time window. The ED(50)
values for the inhibition of SWDs by LY 300164 and CGP
36742 in a time window 30–60min after injection were
15.5 and 16.6mg/kg, respectively. The ED(50) of CGP
36742 was reduced to 8.0mg/kg when this antagonist was
administered in combination with LY 300164 (6mg/kg).
0 5 10 15 20
0
5
10
15
20
0
25
50
75
100
1 10 100
LY 300164
0
CGP 36742
CG
P 
36
74
2 
(m
g/
kg
)
LY 300164 (mg/kg)
Dose (mg/kg)
CGP 36742 + LY 300164 (6 mg/kg)
N
or
m
al
iz
ed
 n
um
be
r
of
SW
D
 (%
)
Dose response curves
30–60 min after injection
Figure 5: Isobologram for the antiabsence interaction between the
GABAB antagonist CGP 36742 and the AMPA receptor antagonist
LY 300164. The ED
50
value of CGP 36742 is plotted on the ordinate
(closed diamond) and that of LY 300164 on the abscissa (closed
square). The ED
50
values (for the inhibition of SWD) were obtained
by fitting data to the sigmoid 𝐸max model, for the data from the time
period 30–60-min after injection (see graph insert and Materials
and Methods section of [135]). The straight line connecting the
two plotted ED
50
values is the isobolographic line, while dotted
lines represent 95% confidence intervals (CIs). The experimental
ED
50
of the combination of CGP 36742 and LY 300164 (6mg/kg)
is plotted as the open circle and 95% CIs as the solid vertical line.
If the experimentally determined ED
50
lies on the isobolographic
line, then the drug effects are additive. If the ED
50
lies below this
line, supra-additivity is assumed and when the ED
50
lies above the
isobolographic line, there is infra-additivity. However, when 95%
CIs of the experimentally obtained combination overlap with the
respective intervals of the isobolographic line, then the interaction
is regarded as statistically nonsignificant. In such case, the observed
interaction seems to be additive (reprinted with permission from
Elsevier, [135]).
The interaction between the two antagonists appeared to be
additive according to isobolographic analysis. The data are
presented in Figure 5.
Importantly, CGP 36742 and LY 300164 administered
either alone or in combination had no apparent effects on
behavior. Their isobolographic method used may provide
information for a rational approach to polytherapy in general
and specifically for the treatment of generalized absence
epilepsy [135].
A similar effect for specific antagonist of GABAB receptor
has been received in the AY-9944 model of atypical absence
epilepsy [136]. The GABAB receptor antagonist CGP 35348,
administered i.p., decreased dose dependently themean burst
times. SWDs were suppressed for at least 4 h after injection of
CGP 35348.
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3.1.3. Physiological Inactivation of GABA. There are two
mechanisms of the physiological inactivation of GABA: high
affinity reuptake of GABA by specific GABA transporters and
enzymatic inactivation of GABA by GABA-transaminase.
The inhibition of both mechanisms of GABA inactivation
by specific agents leads to a substantial increase of GABA
concentration in the synaptic cleft.
In a series of clinical reports the development of non-
convulsive status epilepticus (NCSE) with electroclinical fea-
tures consistent with those of atypical absence seizures after
adjunctive antiepileptic therapy of tiagabine (an inhibitor
of GABA reuptake) was described. The patient, a boy of 7
years, suffered from frequent myoclonic seizures and rare
atypical absences, tonic, atonic, and simple partial seizures
of unknown etiology. The interictal EEG showed generalized
sharp waves and/or 2–2.5Hz. NCSE developed when rapid
dosage increase and high dose of tiagabine was given [137].
In two other reports, it was described that tiagabine induced
NCSE in patients with focal epilepsies and in one patient
with juvenile myoclonic epilepsy. A 32-year-old patient
with absence epilepsy and primary generalized tonic-clonic
seizures since 11 years of age was described, who developed
her first NCSE while treated with 45mg of tiagabine daily
[138]. Three other cases with focal lesional epilepsy had
nonconvulsive status epilepticus induced by treatment with
tiagabine [139].
These clinical cases were predicted based on results in the
genetic absence models: effects of tiagabine in various doses
were investigated on EEG, two types of SWDs, and behavior
of WAG/Rij rats. WAG/Rij rats have two types of SWDs, the
most common ones, bilateral symmetrical and generalized
(type I), and more occipital, shorter lasting SWDs (type
II). According to expectations from other GABAmimetics,
Tiagabine enhanced in a dose-related way both the number
and mean duration of both types of SWDs. The low dose of
1mg/kg had almost no effects, but doses of 3 and 10mg/kg
were effective. Furthermore, tiagabine in the latter two doses
increased the power in the higher 𝛽 band of the background
EEG, whereas no significant changes in behavior of the rats
were found. In general, this experiment supports that non-
convulsive epilepsy is associatedwith aGABAhyperfunction.
It also underlines the biochemical differences of convulsive
and nonconvulsive animal models of epilepsy since tiagabine
is rather effective in blocking convulsive seizures; it belongs
to the category of drugs effective in convulsive animalmodels
and not in nonconvulsive models of epilepsy [1].
The limbic system is generally not included in any
theory (for review see [7]) about the pathogenesis of absence
seizures. However, some data demonstrated that the alter-
ations in the limbic system attribute to the expression of
absence epileptic phenotype in genetic models of absence
epilepsy [140]. Tolmacheva and van Luijtelaar [141] investi-
gated whether local intrahippocampal administration of the
neurosteroid progesterone and the GABA reuptake inhibitor
tiagabine might affect the occurrence of SWDs. WAG/Rij
rats received intracerebral injections of progesterone, 45% 𝛽-
cyclodextrin (CD), saline, or tiagabine. EEG recordingsmade
before and after injection showed that progesterone, CD,
and tiagabine administration to the hippocampus reduced
SWDs for 60min following administration without behav-
ioral or electroencephalographic side-effects. Both proges-
terone administration into the cortex and saline injection
into the hippocampus yielded no changes in the occurrence
of SWDs. These data suggest that activation of GABAergic
transmission in the hippocampus has an inhibitory effect on
corticothalamocortical circuits underlying the generation of
SWDs and might be critically involved in the regulation of
absence seizures in the corticothalamocortical network.
Tiagabine increases absence seizures also in the other
genetic absence models such as after systemic administration
in GAERS and in the lethargic mouse models [2, 142].
The intensification of the efficiency of the GABAer-
gic system by vigabatrin, a GABA-transaminase inhibitor,
causes also an increase of absences. Vigabatrin but also
carbamazepine and phenytoin are contraindicated in typical
absence seizures [143]. Yang et al. [144] presented three
patients with de novo absence epilepsy after administration
of carbamazepine and vigabatrin with different types of
epilepsy. In a second clinical study 14 patients (seven male),
aged 15–46 years, and with a mean duration of epilepsy of
16.4 years were identified. Video-EEG demonstrated typical
absence status epilepticus in five, atypical status epilepticus
in five, atypical myoclonic status epilepticus in three and
typical myoclonic status epilepticus in one. Epilepsy had
been misclassified as cryptogenic partial in eight cases and
cryptogenic generalized in four.The correct diagnosis proved
to be juvenile absence epilepsy in six patients, juvenile
myoclonic epilepsy in four, epilepsy with generalized tonic-
clonic seizures on awakening in two, and childhood absence
epilepsy in two. All patients had been treated with car-
bamazepine (CBZ) and had experienced seizure aggrava-
tion or new seizure types before referral. Seven patients
had polytherapy with phenytoin, vigabatrin, or gabapentin.
Potential precipitating factors included dose increase of
carbamazepine or of carbamazepine andphenytoin; initiation
of carbamazepine, vigabatrin, or gabapentin; decrease of
phenobarbital. Withdrawal of the aggravating agents and
adjustment of medication resulted in full seizure control.
This series shows that severe pharmacodynamic aggravation
of seizures in idiopathic generalized epilepsy may result in
absence status epilepticus or myoclonic status epilepticus,
often with atypical features [145].
The effects of vigabatrin on type II SWDs in the EEG of
ACI rats were studied in order to learn more about the effects
of alteringGABA concentration on SWDs.The incidence and
mean duration of type II SWDs increased after vigabatrin as
compared to saline. This effect appeared with a halftime of
100min. The peak frequency of the type II SWDs decreased
after vigabatrin (5.6Hz) as compared to saline treatment
(7.5Hz).Thus, vigabatrin alters the type II SWDmorphology.
These results are in agreement with predictions of Destexhe’s
theoretical model, modulating both GABAA and GABAB
conductance’s [146]. The effect of vigabatrin on the starting
and the stopping mechanisms (the latter was determined by
the hazard function) was also investigated in WAG/Rij rats.
This experiment showed that a high GABA level changed
the stopping mechanism of the absence epileptic seizures,
creating much better conditions for very long seizures to
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occur. With respect to the starting mechanism, it was found
that both with a high and a low GABA level, there was
evidence for a recovery mechanism that decreases the prob-
ability that a new seizure starts. Another possibility is that
the brain protects itself from a subsequent absence seizure, an
endogenous protection mechanism; this has been described
for the hippocampus by Kelly and McIntyre [147] and for
acute PTZ seizures [148]. Initially this probability is lower
with high GABA concentrations, but gradually it converges
to the same constant baseline probability as in the condition
with a low GABA concentration [149].
Other inhibitors of GABA catabolism such as 𝛾-vinyl
GABA (GVG) also increase SWDs, as demonstrated in
GAERS [115, 125, 150].
Thus, pharmacological research of GABAA and GABAB
receptors and of GABA inactivation mechanisms specifies
the basic strengthened role of the GABAergic system on
absence seizures. Such conclusion can be made on the basis
of that in the overwhelming majority agonists of GABA
receptors after systemic injections increase SWD activity (an
exception are the benzodiazepines), and antagonists reduce
them. Besides strengthening of GABAergic neurotransmis-
sion, amore exact prolongation ofGABA effects by inhibition
of GABA inactivation mechanisms also increases absences.
Local injections of GABA mimetic drugs may show opposite
effects, so that one can conclude that absence seizure is
not due to a global increase in inhibition, but to localized
increased and decreased sites of inhibition. The increase
of SWDs by GABA agonists confirms our assumption that
the hyperpolarization-induced 𝐼h pacemaker in the thalamus
contributes to the occurrence of SWDs. The composition of
the 𝐼h channel isoforms in the focal region of the cortex, the
putative presence of 𝐼h on GABA interneurons in different
part of the brain, together with the found opposite actions
of GABA agonists in cortex and thalamus, might give room
for another collaboration between 𝐼h and (𝐼Ca,T).
3.2. Measurement of GABAergic System Efficiency. One of
the methods to estimate the efficiency of neurotransmitter
systems is to determine the binding constants of a labeled
ligand with a receptor; it characterizes the activity of a recep-
tor. By the help of specific concentration-dependent kinetic
reactions and equations describing them, the dissociation
constant (𝐾d) and density of a receptor (𝐵max) type are
defined. Rate of direct and reverse reactions of interaction
(i.e., rate of association and dissociation) depends on the
concentration of the ligand. The dissociation constant (𝐾d)
is the concentration ligand at which the rate of direct and
reverse reactions is equal, then the rate of association is
equal to the rate of dissociation. The 𝐾d defines the affinity
of a ligand with a receptor. The general pool of receptors
in a membrane can be in two states: closed state (receptors
immerse in the cell membrane, with such type of receptors
binding is not carried out) and in open state, when receptor
binding takes place. An increase of receptor density (𝐵max)
implies an increase in the quantity of the active centers of
binding. Based on 𝐾d and 𝐵max, it is possible to characterize
receptors. A reduction of𝐾d (without changes in𝐵max)means
increase in affinity of receptors, strengthening of efficiency
of the reaction of the receptors to the most sensitive and
intensive part of a receptor. An increase of 𝐵max (without
change in 𝐾d) means strengthening of receptors reaction
efficiency to all concentrations tested.
In vitro, the binding parameters of 3H-Ro 5-4864, a
ligand labeling the peripheral benzodiazepine receptor, were
determined for brain homogenates of WAG/Rij and ACI
rats. No difference in 𝐾d, but a significant decrease (25%)
in WAG/Rij rats receptors 𝐵max, was found [151]. Autora-
diography was used to study the binding of [3H]-GABA
with GABAA and GABAB receptors in brains from GAERS:
both the density of GABAA or GABAB receptors and affinity
of these receptors to GABA were determined. No differ-
ence in the density of GABAA and GABAB receptors and
affinity of these receptors to GABA between control and
epileptic animals were found [152]. The regional distribution
of radioactive ligand binding for different receptors of the
GABAA-benzodiazepine-picrotoxin chloride channel com-
plex was measured on tissue section by autoradiography
in brains taken from GAERS and controls. The ligands
employed included [3H]muscimol for high affinity GABA
agonists sites; [3H]SR 95531 for the low-affinity GABA sites;
[
3H]flunitrazepam for the benzodiazepine sites; and [35S]t-
butyl bicyclophosphorothionate (TBPS) for the picrotoxin
site. There were no significant differences between GAERS
and control animals in [3H]flunitrazepam and [35S]TBPS
binding. However, there was a decreased [3H]muscimol and
[
3H]SR 95531 𝐵max in the CA2 region of the hippocampus
in GAERS. It is necessary to note once more that the
hippocampus is traditionally not considered as a structure
in which SWDs can be measured [4, 21, 153], although
recent data in GAERS and WAG/Rij rats point towards
alternations in the limbic system as a consequence of the
hundreds daily SWDs [41, 140]. Another study explored a
possible role of GABAB receptors in absence seizures in
lethargic (lh/lh) mice. [3H]baclofen binding to neocortical
plasma membranes prepared from lh/lh and wild (+/+) age-
matched congenic mice was measured. The 𝐵max of GABAB
receptors was 20% larger in lh/lh than in +/+ mice in an age-
independent manner. Interestingly, the subset of lh/lh mice
with larger seizure frequency (40–70 seizures/15min) had a
significantly greater 𝐵max than the subset with lower seizure
frequency (1–10 seizures/15min). The increase of GABAB
receptor density was selective, because binding to glutamate
receptors ([3H]glutamate binding) and to GABAA receptors
([3H]muscimol binding) was not significantly different in
the two strains. The authors suggest that higher density of
GABAB receptors in lh/lh mice underlies the expression
of absence seizures in this model [154]. GABA and the
enzyme of its synthesis, glutamic acid decarboxylase (GAD),
was investigated in cortex and thalamus of GAERS by
immunocytochemistry; theGABAA receptors were evaluated
by autoradiography of 3H-flunitrazepam binding and by
immunocytochemistry using specific antibodies against the
𝛽2-𝛽3 subunits of GABAA receptor protein. GABA and GAD
immunocytochemistry did not show any difference in density
or distribution of immunoreactive elements (fibers, terminals
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and neurons) between epileptic and control animals, but
autoradiographic and immunocytochemical studies showed
a decreased enhancement of 3H-flunitrazepam binding and
of 𝛽2-𝛽3 subunits of GABAA receptor in the sensory-motor
cortex and anterior thalamic areas of the epileptic strain. No
differences were found in benzodiazepine receptors in the
two strains. GABAB receptors were measured as
3H-baclofen
binding in a crude synaptic membrane preparation and there
was no difference between epileptic and control animals.
The data suggest an impairment of the “GABAA system” in
studied brain regions of epileptic rats, due to a reduction
of receptor 𝛽2-𝛽3 subunits and coupling to benzodiazepine
receptors despite the normal synthesis and location of the
neurotransmitter [155]. The effect of GHBA-induced SWDs
on the function of various components of the GABAA recep-
tor complex in the cortex of the rat was determined in a series
of in vitro experiments. GHBA itself without SWDs had no
effect on the binding of [3H]muscimol, [3H]flunitrazepam,
and [35S]TBPS or on the uptake of 36Cl− into synaptoneu-
rosomes in the in vitro studies. However, at the onset
of GHBA-induced SWDs, there was a significant decrease
in the binding of [35S]TBPS, associated with a significant
decrease in muscimol-stimulated uptake of 36Cl− with no
other biochemical change. One minute after onset of GHBA-
induced absence seizures, a significant increase in the binding
of [3H]muscimol was noted. Tenminutes later the decrease in
muscimol-stimulated uptake of 36Cl− had normalized, while
the changes in binding of [3H]muscimol and [35S]TBPS per-
sisted [156].The analysis of extra- and intracellularly recorded
synaptic responses revealed an intracortical hyperexcitability
which was accompanied by a significant reduction in the
efficiency of GABAergic inhibition. These data indicate that
the imbalance between intracortical excitatory and inhibitory
mechanisms may at least contribute to the expression and
augmentation of SWDs in WAG/Rij rats, and this was also
found in an in vitro neurophysiologic study [157]. Leaning on
the known fact, that postsynaptic GABAB receptor-mediated
events are reduced after prior treatment with pertussis toxin
(PTx), the influence of PTx (0.4microg), denatured-PTx or
vehicle saline bilaterally injected into the relay nuclei of the
thalamus in anesthetized GAERS were studied for up to 6
days, following which the brains were removed and GABAB
or GABAA receptor autoradiography was performed. By 6
days the SWD of the rats treated with PTx was suppressed
by 96% compared with vehicle-injected rats with a significant
(62%) reduction even after 1 day. Denatured toxin had no
effect. After 6 days GABAB, but not GABAA, receptor binding
was significantly reduced by 70–80% in the ventrolateral
and ventral posterolateral thalamic nuclei [158]. In the same
model, the high affinity binding of GABAA/BZD receptors
with (3H)RO 15-1788 in the brain of naive rats and after
administration of FG 7142 did not differ in GAERS and
nonepileptic control rats [112]. The authors suggested that
the hypersensitivity of GAERS to various inverse agonists of
theGABAA/BDZ receptor involves corticalGABAA receptors
and is not related to differential activity of a subunit-selective
receptor.
Miniature GABAA IPSCs recorded in the VB complex of
the thalamus, and in cortical layer II/III neurons were similar
in GAERS and nonepileptic controls, whereas in GAERS
RTN neurons had a 25% larger amplitude and 40% faster
decay. In addition, baclofen was significantly less effective
in decreasing the frequency of RTN mIPSCs in GAERS
than in control, whereas no difference was observed for
cortical and VB mIPSCs between the two strains. Paired-
pulse depression was 45% smaller in GAERS RTN, but not
in VB, and was insensitive to GABAB antagonists. These
results point to subtle, nucleus-specific, GABAA receptor
abnormalities underlying SWDs rather than a full block
of these receptors across the whole corticothalamocortical
network. Their occurrence prior to seizure onset suggests
that they might be critically involved in epileptogenesis
[160].
We have studied muscimol-induced 36Cl− conductiv-
ity in synaptoneurosomes prepared from the frontal and
somatosensory cortex of rats with three types of epileptic
activity: tonic-clonic pentylenetetrazole kindling in Wistar
rats, nonconvulsive absence PTZ kindling in Wistar rats (an
absence seizure model), WAG/Rij and Wistar control rats
[159]. We used two concentrations of muscimol: 30 and
100 𝜇M. The occurrence of kindling prior to tonic-clonic
seizures in the Wistar rats decreased the muscimol-induced
36Cl− conductivity compared to control (Figure 6(a)). Devel-
opment of nonconvulsive kindling considerably increased
36Cl− conductance into the neocortical synaptoneurosomes.
WAG/Rij rats showed an increase in 36Cl− conductance in
neocortical synaptoneurosomes as compared to the control
Wistar rats (Figure 6(b)). The decrease in muscimol-induced
36Cl− conductivity after development of tonic-clonic kindling
was in agreement with a quite some amount of data regarding
the decrease in the activity of GABAA receptor during tonic-
clonic kindling [55, 161–165]. The high level of muscimol-
induced 36Cl− conductivity in the neocortical synaptoneu-
rosomes of the WAG/Rij rats supported the concept that
the SWDs originating from the somatosensory cortex are
induced by hyperpolarization. The high level of 36Cl− con-
ductivity during nonconvulsive PTZ kindling suggests that
the activity of the GABAA receptor was similar in the genetic
absence epilepsy model and PTZ absence seizure model.
The binding of [11C]flumazenil at the BDZ site of the
GABAA receptor was studied in five patients with idiopathic
generalized epilepsy with positron emission tomography. No
evidence was found for a change in [11C]flumazenil binding
with absence seizures [166]. However, these early studies were
not aimed at the cortex, the most likely location of the origin
of SWDs.
Except for binding constants of labeled ligands with
GABAA and GABAB receptors defining efficiency of
GABAergic, other parameters defining efficiency of GABA-
ergic transmission have been used. Levels of extracellular
GABA and other amino acids in the ventrolateral thalamus
in GAERS have been monitored with in vivo microdialysis.
It was shown that the basal extracellular levels of GABA and,
to a lesser extent, taurine were increased when compared
with values in nonepileptic controls. However, modifying
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Figure 6: Muscimol-induced 36Cl− conductivity (nmole/mg of protein) inside synaptoneurosomes prepared from the neocortex of 3-4-
month-old control Wistar rats (a) and Wistar rats with PTZ-induced convulsive kindling and 5-6-month-old control Wistar and WAG/Rij
rats (b). ∗𝑃 < 0.05 (with permission from Springer, [159]).
GABAergic transmission with the GABAB agonist (−)-
baclofen, the GABAB antagonist CGP-35348, or the GABA
uptake inhibitor tiagabine did not produce any further
alteration in extracellular GABA levels [167]. Another
study was performed to test the hypothesis that presynaptic
GABAB receptors in lh/lh mice inhibit [
3H]GABA release
to a greater degree than nonepileptic littermates (designated
+/+). Synaptosomes isolated from neocortex and thalamus
of age-matched lh/lh and +/+ mice were similar in uptake
of [3H]GABA. In the neocortical preparation, baclofen dose
dependently inhibited [3H]GABA release evoked by 12mM
KCl, an effect mediated by GABAB receptors. The maximal
inhibition (𝐼max) value was significantly greater (80%) in
lh/lh than in +/+ mice, whereas the IC50 (3microM) was
unchanged. The effect of baclofen (50microM) was 58%
less robust in thalamic preparation of the lh/lh mice. Other
effects mediated by GABAB receptors (inhibitions in Ca
2+
uptake and cAMP formation) were also significantly reduced
in thalamic synaptosomes from lh/lh mice. It is possible that
selective effects of presynaptic GABAB receptors or GABA
release in neocortex and thalamic nuclei of lh/lh mice may
contribute to mechanisms underlying absence seizures [168].
K+ conductance of GABAB receptor activation by baclofen
was subsequently studied. Whole-cell voltage-clamp
recordings were made from thalamic ventrobasal neurons
of age-matched lethargic (lh/lh) and wildtype (+/+) mice.
No essential distinctions were found [169]. GABA release
and uptake were examined in GAERS and in nonepileptic
control animals, using crude synaptosomes prepared from
the cerebral cortex and thalamus. Uptake of [3H]GABA over
time was reduced in thalamic synaptosomes from epileptic
rats, compared to controls. The affinity of the uptake process
in thalamic synaptosomes was lower in epileptic animals.
NNC-711, a ligand for the GAT-1 uptake protein, reduced
synaptosomal uptake by more than 95%; 𝛽-alanine, an
inhibitor selective for the uptake proteins GAT-2 and GAT-3,
did not significantly reduce synaptosomal uptake. These
results indicate that GABA uptake in the thalamus of GAERS
rats was reduced compared to control animals. The lower
level of uptake in the epileptic animals corresponds to higher
efficiency of GABA system in these rats [170].
Progesterone and estradiol serum levels were investi-
gated in WAG/Rij rats before, during, and after pregnancy
following parturition. The serum concentration of proges-
terone increased after the 3rd day of pregnancy. Levels
of estradiol changed less. Progesterone is kept high until
the 18th day of pregnancy and drastically decreased before
the parturition. Common duration of absences-spontaneous
SWD, frequency, and the duration of every SWD decreased
from 3rd to 19th days of pregnancy before parturition. On
the basis of these data and regulation of GABAA receptor
efficiency by neurosteroids [116], it can be assumed that the
changes in the parameters of SWD are possibly correlated
with changes in progesterone in serum during pregnancy
[171, 172].
A time course study that examined the effects of the
female estrous cycle on themore slow atypical SWDs,GABAB
receptor binding, and GABAB receptor protein expression
was conducted in the AY9944 model in Long-Evans rats.
There was a significant increase in both the duration of
ISRN Neurology 15
SWDs and GABAB receptor binding during the proestrus
stage of the estrus cycle, the stage during which the levels of
progesterone are at their highest. No changes in GABABR1
or R2 protein levels were observed. These data suggest an
important role for steroid hormones and its interaction
with GABA receptors in the regulation and maintenance
of AY9944-induced atypical absence seizures [123]. Brain
cholesterol synthesis inhibition (CSI) at a young age in rats
has been shown to be a faithful model of the symptomatic
generalized epilepsies, in this case acquired absence epilepsy,
a devastating condition for which few therapies or models
exist. The CSI model was used to study cellular mechanisms.
Patch-clamp and whole-cell recordings were compared from
neurons acutely dissociated from the RTN in Long-Evans
Hooded rats treated and untreated with the cholesterol syn-
thesis inhibitor U18666A. In U18666A-treated animals, 91%
of rats developed SWDs. Relevant is also thatmutations of the
𝛾2 subunit of the GABAA receptor abolish natural sensitivity
to BDZ [173]. Patch-clamp results revealed that although
there was no remarkable change in GABAA receptor affinity,
both a loss of ability of benzodiazepines to enhance GABAA-
receptor responses and an increase of Zn2+ inhibition of
GABAA-receptor responses of RTN neurons occurred in
this model. This change was specific, since no significant
changes were found in neurons exposed to the GABA
allosteric modulator pentobarbital. Taken collectively, these
findings provide evidence for abnormalities in BDZ and Zn2+
modulation of GABAA receptors in the cholesterol synthesis
inhibition model and suggest that decreased 𝛾2 subunit
expression may underlie important aspects of generation of
TCSWDs in atypical absence seizures. The present results
are also consistent with recent findings that mutation of the
𝛾2 subunit of the GABAA receptor changes benzodiazepine
modulation in families with generalized epilepsy syndromes
[174].
It is known that basket cells typically express two calcium-
binding proteins, parvalbumin (PV) and calbindin. PV is co-
expressed with GABA in 90% of the GABAergic neurons
[175, 176], and PV-immunostaining is an appropriate way to
mark basket cells [177]. Quantification of PV-positive cells
showed clear reductions in the parietal and forelimb area
of the somatosensory cortex in WAG/Rij rats compared to
nonepileptic control ACI rats.These results are interpreted as
deficiency of Ca2+-binding protein in corresponding struc-
tures of the brain of WAG/Rij rats [178], or as deficiency of
GABAergic cells [9].
Thus, the measurement of efficiency of the GABAergic
system in various absence models leads to the conclusion
that a huge variety of experiments demonstrate a large role
for deficiencies in the GABAergic system. However, there are
also diverse results, among others with the role of GABAB.
We see three reasons for this; different seizure or epilepsy
models were used. It is possible that different deficiencies and
different mechanisms may all lead to the same phenotype:
SWDs. The second reason of the diverse results is the so-
called process of uncertainty of the nervous system [179].
The analysis of several works has shown that increase or
decrease of general activity of the neurotransmission system
at different animals can be carried out by different ways
and depends on specific features of these animals. The third
reason for the occurrence of diverse results can be processes
of indemnification (protection against injury). To illustrate,
in our study of synaptoneurosomes, samples from cortex of
Wistar and WAG/Rij rats were leveled on protein [159] and
on concentration of GABAA receptors. In these conditions
conductivity of chlorine was higher inWAG/Rij rats. In brain
tissue, in which GABA systems have been reduced [9], a
reduction of the quantity of GABAA receptor can be found
and a reduction of inhibition. In this case strengthening of
conductivity of chlorine through GABAA receptors can be
considered as compensation for the reduced functioning of
GABA systems.
3.3. Subunit Composition and Mutation of GABA
𝐴
Receptor
3.3.1.Molecular Structure of GABA
𝐴
Receptor. GABAA recep-
tors concern an ionotropic super family of receptors repre-
senting a pentahedron [180]. Five subunits of GABAA recep-
tor surround the Cl− channel [105–107, 181, 182]. GABAA
receptor subunits are a long polypeptide which penetrates a
membrane in four places, that is why subunits possess four
transmembrane domains. The so-called N- and C-terminals
of the polypeptide are located on the extracellular surface.
It is supposed that the second domain of GABAA receptor
subunit covers a wall of the chloride channel [183]. Between
the third and fourth domains, there is a large intracellular
fragment to which sites of protein kinase phosphorilation are
concentrated and with which the basic differences in primary
structure between various subunits are connected [181, 184].
On theN-terminal of the polypeptide leaving the first domain
is the active center of a receptor or the sites connecting with
ligands [105, 185–187].
Some specific binding sites are located on the GABAA
receptor [105, 182]. The first site is the GABA site where
binding to GABA and its specific agonists such as gaboxadol,
ibotenic acid, muscimol, and progabide takes place and to
antagonists such as bicuculline and gabazine. Next there
is the site of positive allosteric modulators such as bar-
biturates, benzodiazepines, carisoprodol, ethanol (alcohol),
etomidate, glutethimide, kavalactones [188], meprobamate,
methaqualone, neuroactive steroids [189, 190], niacin/niaci-
namide, nonbenzodiazepines, propofol, theamine, valerenic
acid, and volatile/inhalation anesthetics. There is also the
site of negative allosteric modulators such as flumazenil,
Ro15-4513 and sarmazenil [191–193] and the site of non-
competitive channel blockers such as cicutoxin, oenantho-
toxin, pentylenetetrazol, picrotoxin, and thujone. According
to the definition, allosteric modulators which bind with
GABAA receptors in places which do not overlap with a
binding site of an agonist, cause conformation reorganiza-
tions and change of receptor efficiency [194]. The chloride
channel opens when two GABA molecules interact with
their own site. Other sites only strengthen or reduce this
interaction. GABA itself is an allosteric regulator for other
sites. Next, the neurosteroid site will be discussed in more
details.
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After interaction of neurosteroids with the GABAA
receptor, an intracellular process, oxygenation, is started; it
transforms some intracellularmetabolites in steroid receptors
ligands [116]. After binding of these ligands with intracellular
steroid receptors, the gene expression is modified. As the
GABA site is an allosteric modulator of neurosteroid site, the
interaction of GABAwith its own site, allosterically modified
by the neurosteroid site, initiates a cascade of events leading
to the start of signal transduction. The transduction signal
started through receptors processes of intracellular phospho-
rilation which terminate in updating the expression of genes.
It means that the GABAA receptor is an ionotropic receptor,
but that it also initiates simultaneously signal transduction.
Why is signal transduction so important? The modification
of genes expression is a unique mechanism of an encoding
process called memory consolidation, that is the transfer of
information from short-term into long-termmemory.Hence,
signal transduction plays an important role at the long-term
storage of information, in learning and memory, in training,
in neuroplasticity in general, and in pathological states.
The GABAA receptor has 22 subunits: 𝛼-6 subtypes, 𝛽-4
subtypes, 𝛾-3 subtypes, 𝛿-1 subtype, 𝜀-3 subtype, 𝜋-1 subtype,
𝜌-3 subtype, and 𝜃-1 subtype [181, 195, 196]. It is necessary
to notice that some isoforms of GABAA receptor subunits
have various variants. So, for 𝛾2 subunit, two variants were
revealed [197, 198], differing in length of an intracellular
fragment between 3 and 4 domains. Similar distinctions
are known for 𝛽2, 𝛽4 subunits for which the presence
of two variants has also been shown [199, 200]. Each of
such sequences (𝛾2, 𝛽2 and 𝛽4) has in the designation an
additional letter L or S (accordingly, long and short) [181].
Two splays variant have been found for the 𝛽3 subunit
[201]. It is supposed, those three splays variants exist for
the 𝛼5 subunit [202]. A product of alternative splicing is
the 𝛼6 subunit, truncated with an N-terminal [203]. The
18 types of GABAA receptor subunits are expressed in a
mammalian brain: 𝛼 subunits (1–6), 𝛽 subunits (1–3), 𝛾
subunits (1–3), 𝜀 subunits (1–3) and on 1 subunits 𝛿, 𝜋 and 𝜎
[204].
Different confirmations of the GABAA receptor are found
throughout the brain, and the most common mammalian
subunits composition is two𝛼1 subunits, two𝛽2 subunits, and
one 𝛾2 subunit assembling in a pentahedron-(𝛼1)
2
(𝛽2)
2
(𝛾2).
Twomolecules ofGABA interactwith two sites, each ofwhich
is located on two N-terminuses from the first domain of 𝛼1
and 𝛽2 subunits. The benzodiazepine site is located on two
N-terminus from the first domain of 𝛼1 and 𝛾2 subunits.
Efficiency of allosteric regulation depends on the subunit
composition of GABAA receptors [205]. Table 1 describes
the degree of allosteric regulation. For example, 80% of
brain GABAA receptors are highly sensitive for diazepam,
10% of receptors have a low sensitivity for diazepam. The
latter is the case if the subunit compositions of GABAA
receptor contain 𝛾1 or 𝛾3 subunits. The 10% of receptors
not sensitive for diazepam have subunit compositions of
GABAA receptor containing 𝛼4 or 𝛼6 subunits. From the
80% of receptors that are highly sensitive for diazepam,
10% is insensitive for zolpidem. This is the case if the sub-
unit composition of GABAA receptor contains a 𝛼5 subunit.
Table 1: Density of [3H] SCH 23390 binding sites in different brain
areas of ACI and WAG/Rij rats (D1 receptors).
Brain regions ACI rats WAG/Rij rats 𝑃 < 0.05
Nucleus accumbens (core) 7.12 ± 0.61 5.86 ± 0.79
Nucleus accumbens (shell) 10.51 ± 0.33 8.96 ± 0.36 0.013
Caudate nucleus (head) 11.14 ± 0.25 8.35 ± 0.23 0.00004
Caudate nucleus (ventral) 11.09 ± 0.56 12.14 ± 0.67
Caudate-putamen 7.75 ± 0.70 8.70 ± 0.36
The other 90% of receptors are zolpidem sensitive. The
composition 𝛼1𝛽2𝛾2 possesses high affinity for zolpidem, and
compositions 𝛼2𝛽3𝛾2 or 𝛼3𝛽3𝛾2 demonstrate low affinity.
Absence epilepsy can be accompanied bymodifications of
GABAA and GABAB receptors subunit composition. Neona-
tal treated rats with AY9944 show an increased occurrence of
SWDswhich correlated significantly with a decreased protein
expression of the GABAA 𝛾2 subunit in RTN and VB nuclei
of the thalamus, but not in somatosensory cortex. Conversely,
𝛼1 subunit expression decreased in somatosensory cortex
in the AY9944 model, but not in the thalamus [206].
The decreased GABAA receptor 𝛾2 subunits in thalamus
and increased in cortex are gender and age specific [207].
These results coincide with data that in human absence
epilepsy is more widespread among women. The synaptic
physiology and network property of mice lacking GABAA
receptor 𝛼3, a subunit that is uniquely expressed in the
thalamus by inhibitory neurons of the RTN, have been
investigated. Deletion of this subunit produced a powerful
compensatory gain in inhibitory postsynaptic response in
the RTN. Although other forms of inhibitory and excitatory
synaptic transmission in the circuit were unchanged, evoked
thalamic oscillationswere strongly dampened in𝛼3 knockout
mice. Furthermore, pharmacologically induced TC absence
seizures displayed a reduction in length and power in 𝛼3
knockout mice. These studies highlight the role of GABAer-
gic inhibitory strength within the RTN in maintenance of
thalamic oscillations and demonstrate that inhibitory intra-
RTN synapses are a critical control point for regulating higher
order corticothalamocortical network activity [208]. The
combination of immunocytochemistry and high-resolution
immunogold electron microscopy was used to study cellular
and subcellular localization of GABAA receptors 𝛼1, 𝛼3, and
𝛽2/𝛽3 subunits in ventral posterior nucleus (VP) and RTN
of WAG/Rij and control Wistar rats. In control rats, 𝛼1
subunits were prominent at inhibitory synapses in VP and
much less prominent in RTN; in contrast, the 𝛼3 subunit was
highly evident at inhibitory synapses in RTN. 𝛽2/𝛽3 subunits
were evenly distributed at inhibitory synapses in both VP
and RTN. Immunogold particles representing all subunits
were concentrated at postsynaptic densities with no extra
synaptic localization. Calculated mean number of particles
for 𝛼1 subunit per postsynaptic density in nonepileptic VP
was 6.1 ± 3.7, for 𝛼3 subunit in RTN, it was 6.6 ± 3.4,
and for 𝛽2/𝛽3 subunits in VP and RTN, the numbers were
3.7 ± 1.3 and 3.5 ± 1.2, respectively. In WAG/Rij rats,
there was a specific loss of 𝛼3 subunit immunoreactivity at
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inhibitory synapses in RTN, without reduction in 𝛼3 subunit
mRNA or significant change in immunostaining for other
markers of RTN cell identity such as GABA or parvalbumin.
𝛼3 immunostaining in cortex was unchanged [47]. These
combined results obtained in mice and rats allow us to
assume that different combinations of subunit compositions
of GABAA receptor in the RTN may contribute to or are the
reason for decreased strength of GABAergic inhibition. The
functional consequence is that when the RTN is stimulated
by the cortex, the thalamic resonance might be larger and
SWDs might last longer. Importantly, the changes in subunit
composition were already present in presymptomatic rats,
suggesting that the changes in the RTN are not caused by the
seizures but that they are a property of WAG/Rij rats.
The possibility that absence seizures cause alterations in
GABAA receptor (𝛼1, 𝛼4, 𝛽2, and 𝛾2) subunit gene expression
in thalamic relay nuclei was also explored, in this case in
an acute absence seizure model, the GHB model [209]. A
marked increase in 𝛼1 mRNA and a corresponding decrease
in 𝛼4 mRNA in thalamic relay nuclei 2–4 h after the onset
of GHB-induced absence seizures (when the seizures were
terminating) were detected. These changes were selective
to these 𝛼 isoforms as neither 𝛽2 nor 𝛾2 mRNA changed
following seizures and occurred only in thalamic relay nuclei
but not in hippocampus. The alterations in 𝛼1 and 𝛼4 mRNA
persisted until about 12 h, and by 24 h after the seizure-
onset the mRNA levels normalized. Blocking GHB-seizures
produced no change in the levels of 𝛼1 and 𝛼4 mRNA in
thalamic relay nuclei, suggesting that seizures themselves
were responsible for mRNA alterations.
The expression of mRNA of GABAB receptor subunit was
studied in WAG/Rij [210] and GAERS [211]. By using Real-
Time PCR, the researchers from the Avoli group have found
that mRNA levels for most GABAB1 subunits are diminished
in epileptic WAG/Rij neocortex as compared with age-
matched nonepileptic controls, whereas GABAB2 mRNA is
unchanged. Next, it was investigated the cellular distribution
of GABAB1 and GABAB2 subunits by confocal microscopy
and it was discovered that GABAB1 subunits fail to localize
in the distal dendrites of WAG/Rij neocortical pyramidal
cells [210]. The authors propose that these alterations may
contribute to neocortical hyperexcitability and thus to SWD
generation in absence epilepsy.
GABAB receptor expression in the somatosensory cortex,
VB, and RTN in GAERS was also investigated [211]. In
situ hybridization results showed a significant increase in
mRNA for GABAB1 in the somatosensory cortex and a
decrease in the ventrobasal thalamic nucleus but not in the
RTN. By contrast, the immunocytochemical data revealed
an increased expression of both GABAB1 and GABAB2
receptor subunits in all regions examined, somatosensory
cortex, ventrobasal thalamic nucleus and RTN. The main
finding was an upregulation of GABAB receptor protein in
the corticothalamic circuit in GAERS compared to controls.
The results, as obtained in GAERS [211] and WAG/Rij [210]
rats seem rather opposite to each other, the hyperexcitability
in WAG/Rij rats strain and a wide spread upregulation of
GABAB receptors. We have proposed (see Sections 3 and 4),
that both of these processes cause the same reaction, increase
of SWD. Perhaps the two opposing processes provide the
same response in different strain of animals.
Mutations in inhibitory GABAA receptor subunit genes
(GABRA1, GABRB3, GABRG2, and GABRD) of human have
been associated with genetic epilepsy syndromes including
childhood absence epilepsy, juvenilemyoclonic epilepsy, pure
febrile seizures, generalized epilepsy with febrile seizures
plus, and Dravet syndrome (DS)/severe myoclonic epilepsy
in infancy. These mutations are found in both translated and
untranslated gene regions and have been shown to affect
the GABAA receptors by altering receptor function and/or
by impairing receptor biogenesis by multiple mechanisms
including reducing subunit mRNA transcription or stability,
impairing subunit folding, stability, or oligomerization and
by inhibiting receptor trafficking [48, 49, 212–222]. Besides,
it is supposed that the chloride channel gene CLCN2 may be
a susceptibility locus in a subset of cases of childhood absence
epilepsy [223].
To understand the effect of these mutations, surface tar-
geting of GABAA receptors was analyzed by subunit-specific
immunofluorescent labeling of living cells. An involvement
of the 𝛾2-Arg-43 domain in the control of receptor assembly
was revealed. This may have some consequences to the effect
of the heterozygous 𝛾2(R43Q)mutation leading to childhood
absence epilepsy and febrile seizure [224].
Stargazer (stg) mutant mice fail to express stargazin
(transmembrane AMPA receptor regulatory protein 𝛾2
(TARP𝛾2)) and consequently experience absence seizure-like
TCSWDs that pervade the hippocampal formation via the
dentate gyrus. As in other seizuremodels, the dentate granule
cells of stg develop elaborate reentrant axon collaterals and
transiently overexpress brain-derived neurotrophic factor.
It was investigated whether GABAergic parameters were
affected by the stg mutation in this brain region. GABAA
receptor 𝛼4 and 𝛽3 subunits were consistently upregulated,
GABAA receptor delta expression appeared to be variably
reduced, whereas GABAA receptor 𝛼1, 𝛽2, and 𝛾2 sub-
units and the GABAA receptor synaptic anchoring protein
gephyrin were essentially unaffected. It was established that
the 𝛼4 𝛽𝛾2 subunit-containing, flunitrazepam-insensitive
subtype of GABAA receptors, not normally a significant
GABAA receptor in dentate gyrus neurons, was strongly
upregulated in stg gyrus neurons, apparently arising at the
expense of extra synaptic 𝛼4 𝛽𝛿-containing receptors. This
change was associated with a reduction in neurosteroid-
sensitive GABAA receptor-mediated tonic current. This
switch in GABAA receptor subtypes was not reciprocated in
the tottering mouse model of absence epilepsy implicating a
unique, intrinsic adaptation of GABAergic networks in stg.
Contrary to previous reports that suggested that TARP𝛾2
is expressed in the dentate, it was found that TARP𝛾2 was
neither detected in stg nor in control dentate gyrus. It was
reported that TARP𝛾8 is the principal TARP isoform found
in the dentate gyrus and that its expression is compro-
mised by the stg mutation. These effects on GABAergic
parameters and TARP𝛾8 expression are likely to arise as a
consequence of failed expression of TARP𝛾2 elsewhere in
the brain, resulting in hyperexcitable inputs to the dentate
[225].
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The expression of one GABAA receptor gene, GABABR1,
is distinguished by the expression of multiple splice vari-
ants that encode different isoforms of the receptor. Two
novel GABABR1 variants, GABABR1h (R1h) and GABABR1i
(R1i), which appear to arise from alternative splicing of
the GABABR1 gene, were identified. The expression of R1h
and R1i is differentially regulated in brain and peripheral
tissues, but expression is not altered in the brain of GAERS.
Both the R1h and R1i variants exhibit a novel 80-bp insert
downstream of exon 4 that is flanked by consensus splice
sites, and both encode C-terminal-truncated proteins. The
new insight into the family of GABABR1 variants gained
from this study identifies exon 4 as a preferred locus, or
as a hot spot for regulated splicing in the GABABR1 gene.
This finding correlates with the microexonic nature of exon
4 (21 bp). Bioinformatic analysis of micro-exon 4 and its
flanking pre-mRNA sequences has revealed multiple, poten-
tially competitive, exonic splicing enhancers that provide a
mechanistic basis for the preponderance of alternative splic-
ing events at this locus. Conservation of GABABR1 micro-
exon 4 across species suggests a conserved functional role,
facilitating either N-terminal protein production or post-
transcriptional gene regulation through regulated splicing
coupled to transcript decay [226].
Mutations in the genes encoding the subunits of the
low-threshold T-type Ca2+ channel (𝐼Ca,T) in patients [44–
46, 227–231] and also in GAERS but not in WAG/Rij rats,
are probably associated with a dysfunction of pacemaker
𝐼h channels in cortex and thalamus. First, it has been
shown that the 𝐼f pacemaker channel in the atrial sinus
node functions in pair with the (𝐼Ca,T) channel [232, 233].
The 𝐼f pacemaker channel in the sinus node opens at
−80mV, and the low-threshold (𝐼Ca,T) channel is activated
at −90mV and fully inactivated at +40mV. Blockage of
the (𝐼Ca,T) channels by low concentrations of NiCl2 dimin-
ishes the spontaneous activity of the 𝐼f channel but does
not affect the (𝐼Ca,T) channel (the L-type Ca
2+ channel).
Participation of the low-threshold (𝐼Ca,T) channel in the
regulation of SWDs has been shown in both WAG/Rij
rats [234] and GAERS rats [75]. There are two centers of
bursting neurons which are activated by hyperpolarization:
the RTN [19–22] as the source for spindle oscillations and
the other is localized in the somatosensory cortex, the
site of origin of SWDs [6, 9, 13, 14]. The somatosensory
cortex is reciprocally connected with the VPM, VPL, and
Posterior nucleus of the thalamus, both the ascending and
descending pathways from VPM and VPL give collaterals
to the RTN, which inhibits thalamic neurons. Interest-
ingly, exactly the thalamus [67] and pyramidal neurons of
cortical layers II, IV, and V of the somatosensory cortex
[73, 74, 81] contain hyperpolarization-activated pacemaker
𝐼h channels. The presence of hyperpolarization-activated
pacemaker 𝐼h channels in the RTN makes them an inter-
esting object in the discussion and analysis of normal and
pathological behavioral and neurophysiologic processes and
mechanisms.
Thus, one of the reasons of the occurrence absence
epilepsy is the mutation of several genes coding of GABAA
receptors which causes abnormal functioning of the GABA-
ergic system. This abnormal functioning of the GABAergic
system and mutations of (𝐼Ca,T) channel, which functions in
a tandem with 𝐼h channel, can lead to the occurrence of
spontaneous SWDs in an EEG.
4. Excitatory Glutamatergic System
It had been shown some time ago that the well-known
noncompetitive NMDA antagonist MK-801 reduced the
number and mean duration of SWD; the drug caused also
large behavioural abnormalities such as head waving and
agitation jeopardizing the interpretation whether the SWDs
were primarily or secondarily (via behavior) affected by
this NMDA antagonist [235]. Intracerebroventricular (i.c.v.)
injection of NMDA induced a dose dependently increase in
the number of SWDs. The competitive NMDA antagonist
2-amino-7-phosphonoheptanoic acid (APH) caused a dose-
dependent reduction in the number and mean duration
of SWDs. The effect of NMDA was blocked completely
by APH [236]. Finally, the anticonvulsant remacemide, a
noncompetitive, low-affinity NMDA receptor antagonist and
its major metabolite FPL 12495 after oral administration
suppressed the number of SWDs inWAG/Rij rats [237]. Inter-
estingly, the mean duration of the few SWDs that persisted,
was prolonged. These results obtained after i.c.v. injections
demonstrated unambiguously that the NMDA receptor is
involved in the control of SWDs. The involvement of other
glutamate receptors such as AMPA and kainate receptors was
also studied by i.c.v. injections of AMPA, GDEE (glutamate
diethyl ester, a non-NMDA receptor antagonists), kainic acid,
and kynurenic acid in WAG/Rij rats [238]. EEG registrations
showed that AMPA dose dependently increased absences
while GDEE caused a dose-dependent decrease. All effects of
GDEE could be blocked by an inactive AMPA dosage. Kainic
acid had no effects on nonconvulsive seizures. Kynurenic
acid decreased dose dependently the incidence of SWDs; this
effect of kynurenic acid could be blocked by a nonconvulsive
dosage of kainic acid. Next the interaction between NMDA
and non-NMDA receptors was studied [239]. Compounds
acting on NMDA (NMDA, APH) and non-NMDA (AMPA,
GDEE, kainic acid, kynurenic acid) receptors were coinjected
i.c.v. It appeared that the epilepsy increase, induced by the
non-NMDA receptor agonist AMPA, and in a less obvious
way, by kainic acid, could be blocked by the NMDA receptor
antagonist APH. The effects of NMDA were completely
blocked by the non-NMDA receptor antagonists GDEE and
kynurenic acid. Kain, the kainate agonist, had no effect
on the number of SWDs, but the antagonist kynurenic
acid decreased the discharges. CNQX, another non-NMDA
antagonist, also reduces the number of SWDs [240].
The glutamate release inhibitor and anticonvulsant lam-
otrigine thought to inhibit the excitatory neurotransmitter
release was indicated for nonconvulsive seizures [241]. Only
in a high dose lamotrigine reduced SWD in WAG/Rij rats,
but in that dose side-effect such as abnormal locomotion,
were also seen [242]. Interestingly, a recent double blind EEG
multicentered controlled study confirmed the poor absence
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suppressive effects of lamotrigine in childhood absence
epilepsy [243].
In other series of experiments, two noncompetitive
AMPA receptor antagonists, CFM-2 and THIQ-10c demon-
strated to antagonize generalized tonic-clonic seizures in
different animal models [100], were evaluated in WAG/Rij
rats. Animals were focally microinjected into specific brain
areas of the corticothalamic circuit and EEGs were recorded.
The focal microinjection of the two AMPA antagonists into
thalamic nuclei (ventralis posteromedialis, RTN, ventralis
posterolateralis) and forelimb region was, generally, not
able to modify the occurrence of SWDs. However, both
compounds were able to reduce the number and duration
of SWDs dose dependently when microinjected into the
perioral region of the primary somatosensory cortex. These
findings suggest that AMPA plays a role in absence epilepsy
and that it depends on the involvement of specific neu-
ronal areas. In the next series of experiments the authors
demonstrated that noncompetitive AMPA receptor antago-
nists alone might not be useful in the treatment of absence
epilepsy because of their low therapeutic index [244]. A
similar low therapeutic index was earlier also found with
the AMPA antagonist 7,8-methylenedioxy-1-(4-aminophe-
nyl)-4-methyl-3-acetyl-4,5-dihydro-2,3-benzodiazepine (LY
300164) [135]. Nevertheless, the results from Citraro et al.
showed that the center in the perioral region of the pri-
mary somatosensory cortex takes the lead or has a more
considerable position in generation SWDs and that the
local strengthening of GABAA receptor activity in RTN
strengthens SWDs [99].
In some studies, the effects of glutamatergic receptors
ligands cannot be explained by a simple interaction at the
receptor. To illustrate, the effects of ketamine, a noncompeti-
tive antagonist at the NMDA receptor, were studied on
the EEG and in the open field in the WAG/Rij rat strain
[245]. Ketamine was systemically administered in a dose
range from 3 to 30mg/kg. Biphasic effects of ketamine
were observed in the EEG. The first phase was a dose
dependent suppression of SWDs, followed by a second phase
characterized by the facilitation of SWDs. This increase was
expressed first as an increased number of SWDs, and later
on as a significant prolongation of individual discharges
and decrease in frequency of SWDs. An obvious amplitude
modulation of the discharges was also found. Ketamine
also produced a dose-related initial behavioral excitation, a
decrease of muscle tone in hind quarters, followed by front
quarters and head, and an absence of locomotor activity.
However, the time course of the behavioral changes was not
in parallel with the complex EEG effects. It can be concluded
that ketamine has more effects on the EEG than previously
assumed which cannot be explained by a simple blockade of
the NMDA receptor. It is proposed that the obtained specific
dynamics of SWDs’ frequency may be caused by changes in
the activity of the corticothalamocortical pacemakers that
are generating SWDs. The following study was conducted
to investigate the effects of two noncompetitive AMPA
receptor antagonists, GYKI 52466 and GYKI 53405 (the
racemate of talampanel, the latter drug is a potent and
selective AMPA-receptor antagonist) on the generation of
SWD parallel with the vigilance and behavioral changes in
WAG/Rij rats [246]. Intraperitoneal administration of GYKI
52466 (1-[4-aminophenyl]-4-methyl-7,8-methylenedioxy-
5H-2,3-benzodiazepine), the prototypic compound of the
2,3-benzodiazepine family acting as an ionotropic glutamate
receptor antagonist, and which unlike the conventional 4,5-
benzodiazepines, does not act on GABAA receptors, caused
a fast dose-dependent increase in the number and total
duration of SWD.These changes were accompanied by dose-
dependent increase in duration of light slow wave sleep and
passive awake, vigilance states associated with the presence
of SWD. In addition a short, transient behavioral activation
occurred that was followed by strong ataxia and immobility,
decrease of active wakefulness and increase in deep slowwave
sleep. GYKI 53405 (7-acetyl-5-(4-aminophenyl)-8-methyl-
8,9-dihydro-7H-1,3-dioxolo[4, 5-b][2, 3]benzodiazepine),
the racemate of talampanel, 16mg/kg, i.p. failed to affect
any measure of SWD and vigilance. When used as a
pretreatment, GYKI 52466 (10mg/kg) slightly attenuated
the SWD-promoting effects of the 5-HT1A receptor agonist
8-OH-DPAT, and it decreased the cumulative duration and
mean duration of the paroxysms.
Interest of researchers has turned into metabotropic
glutamate receptors (mGluR’s) since their effects are more
subtle and allow for a more refined intervention than would
be the case with the ionotropic glutamate receptors. MGluRs
are positioned at synapses of the corticothalamocortical
network crucial for the occurrence of SWDs. mGluRs form
a family of eight subtypes subdivided into three groups on
the basis of amino acid sequence, pharmacologic profile, and
G-protein coupling [247–249]. Group I comprises mGlu1
and mGlu5 receptors, which are coupled to Gq proteins.
Their activation stimulates polyphosphoinositide hydrolysis
with ensuing formation of inositol-1,4,5-trisphosphate and
diacylglycerol. The receptors of this group also regulate the
activity of different types of Ca2+ and K+ channels [250].
Group II includes mGlu2 and mGlu3 receptors and they are
coupled to Gi/Go proteins. They negatively modulate the
activity of adenyl cyclase and voltage-sensitive Ca2+ channels
(VSCCs). Group III comprises mGlu4, mGlu6, mGlu7, and
mGlu8 receptors, which are also coupled to Gi/Go proteins.
The individual receptor subtypes have a modulatory role
on excitatory and inhibitory synaptic transmission in the
corticothalamocortical circuitry. Until now, receptors from
all three groups have been studied in WAG/Rij rats.
Group ImGluRs are preferentially localized in the periph-
eral portion of the postsynaptic density of both TCand cor-
ticothalamic cells, where they generate excitatory responses
and regulate mechanisms of synaptic plasticity. Group II and
III mGluRs are found preferentially (albeit not exclusively)
in presynaptic terminals, where they negatively regulate
neurotransmitter release [251].
Group I. mGlu1a receptor expression is reduced in the VB
nucleus of the thalamus and pharmacologic potentiation of
mGlu1 receptors with the selective PAM, SYN119 (corre-
sponding to Ro0711401), reduces the incidence of absence
seizures, whereas treatment with the mGlu1 receptor NAM
(JNJ16259685) exacerbates SWDs [248, 249].
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The expression of mGlu5 receptors was increased in the
somatosensory cortex and decreased in the VB. Interestingly,
these changes preceded the onset of the epileptic phenotype.
SWDs in symptomatic WAG/Rij rats were not influenced by
pharmacological blockade of mGlu5 receptors with MTEP,
but were significantly decreased by mGlu5 receptor potentia-
tion with the novel enhancer, VU0360172-6 without affecting
motor behaviour. The effect of VU0360172-6 was prevented
by cotreatment with MTEP [252]. It seems that PAMs
affecting Group I mGluRs might be interesting new targets
against absence epilepsy.
The outcomes do contrast with data obtained in the
lethargic (lh/hl) mice model, where mGlu1 receptor blockade
with the orthosteric antagonists, AIDA or LY367385, reduces
the incidence of SWDs [253]. Therefore, it appears that the
role of mGlu1 receptors in the regulation of pathologic SWDs
is species/model dependent and may also depend on the
genetic determinants of absence epilepsy.
Group II. Symptomatic WAG/Rij rats showed an increased
expression of mGlu2/3 receptors in the ventrolateral regions
of the somatosensory cortex, ventrobasal thalamic nuclei, and
hippocampus, but not in the RTN and in the corpus striatum,
as assessed by immunohistochemistry and Western blotting
[254]. In contrast, mGlu2/3 receptor signalling was reduced
in slices prepared from the somatosensory cortex of these
symptomatic rats, as assessed by the ability of the agonist,
LY379268, to inhibit forskolin-stimulated cAMP formation.
It therefore seems that mGlu2/3 receptors are involved in
the generation of SWDs and that an upregulation of these
receptors in the somatosensory cortex might be involved in
the pathogenesis of absence epilepsy.
Group III. Studies towards the role of receptors of this cate-
gory have been limited because of lack of specific agonists.
They are, however, interesting for absence epilepsy consid-
ering that activation of these receptors reduces GABAer-
gic inhibitory responses within the thalamus, possibly via
a presynaptic mechanism [255–257]. In addition, they
have a profound effect in reducing the corticothalamic
input onto thalamic relay cells [258]. Interestingly, and
accordingly, an increased incidence of SWDs has been
found in WAG/Rij rats when treated with the selective
mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cy-
clopropa[b]chromen-1a-carboxamide (PHCCC) [259]. In
humans, the mGlu4 receptor gene is localized at a suscepti-
bility locus for juvenile myoclonic epilepsy [260, 261], which
is characterized by absence seizures in addition tomyoclonus
and tonic-clonic seizures. Another group-III mGlu receptor,
the mGlu7 receptor, is also associated with the development
of absence seizures. Mutant mice in which mGlu7 receptors
failed to interact with PICK1 (protein interacting with C
kinase 1) develop absence seizures [262, 263], as do mice
injected with a peptide that disrupts the interaction between
mGlu7 receptors and PICK1 [262]. The precise mechanism
whereby an interaction between mGlu7 receptors and PICK1
restrains SWDs in the corticothalamic network remains to be
determined.
Thus, despite of the somewhat atypical features of the
action of some substances on SWDs, it is possible to conclude
that the role of the glutamatergic system in absence epilepsy
corresponds to its role in idiopathic convulsive epilepsy.
Seizures typical for both nonconvulsive and convulsive
epilepsy could be due to the strengthened functioning of
the glutamatergic system, which might be considered as
hyperexcitability [157, 264]. The results suggest that the three
types of ionotropic excitatory glutamate receptors enhance
SWDs and this alleviating influence can be explained as
follows. The spike in the SWD appears as a rebound spike,
in fact it is the low threshold Ca2+ spike (Figure 1(b)). It
appears after the hyperpolarization phase when the gating
mechanism of an 𝐼h channel is activated.Then the spike or the
depolarization returns again to the hyperpolarization phase,
and the process is repeated. The effects of all three types of
excitatory glutamate receptors consist in the enhancement of
the depolarization phase, that is, in increasing the amplitude
of the spike. A larger spike increases the amplitude of the
hyperpolarization, which in turn increases the subsequent
spike [265]. This process appears as enhanced SWDs in the
EEG. Besides, it is known from classical neurophysiology
[266] that intensification of depolarization enlarges the fre-
quency of action potentials, which are indeed crowned on the
Ca2+ spike.
5. Dopaminergic System of the Brain
5.1. Structure and Function of Mesencephalon DA Systems.
It is well known [267–269] that midbrain DA neurons are
comprised of three groups of cells: A8, A9, and A10. The A10
DA neurons are located in the ventral tegmental area (VTA),
whereas the more lateral DA cells of the substantia nigra pars
compacta (SNpc) belong to the A9 cell group; the A8 neurons
take a more caudal position in the retrorubral field (RRF)
of the midbrain (Figure 7). The terminals of these neuron
groups form the nigrostriatal and mesolimbic (or mesocor-
ticolimbic) DAergic systems. A9 neurons group originating
fromSNpc predominantly forms the nigrostriatal system.The
terminals of these cells innervate the caudate nucleus and
neostriatum. The terminals of A10 VTA neurons innervate
the mesolimbic system: hypothalamus, nucleus accumbens
(Nab, the nucleus of the ventral striatum), olfactory tubercle,
central and basal nucleus of amygdala, habenula, septum,
hippocampus, prefrontal, cingulate, and entorhinal cortex.
The mesocortical DAergic system is predominantly formed
by A10 and partly by A8 neurons.The area of innervations by
this system is the prefrontal, anterior cingulate, entorhinal,
and piriform cortex and deep layer of the frontal cortex. The
DA terminals innervate also the visual and motor cortex.
There are 5 types of metabotropic DA receptors asso-
ciated with G proteins [270, 271] D
1
, D
2
, D
3
, D
4
, and D
5
.
They belong to two basic families of receptors: the D
1
-like
receptors including D
1
and D
5
DA receptors, the D
2
-like
receptors includingD
2
, D
3
, andD
4
DA receptors.TheD
1
-like
receptors are associated with GS proteins; they increase cyclic
nucleotides (cAMP) synthesis and produce upregulation of
DA-induced intracellular events such as phosphorilation
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Figure 7: Schematic presentation of the efferent projections of the A8, A9, and A10 dopamine cell groups. The projection fields of the A10
neurons are designated by vertical hatching, those of the A9 cells by horizontal hatching, and the targets of the A8 DA neurons by diagonal
hatching. Hatching is not intended to indicate the density of the various projections (scheme modified from [267]).
leading to an alteration in cellular activity and changes in
the gene expression within the responding cells. The D
2
-like
receptors are associated with Gi proteins; they decrease cyclic
nucleotides (cAMP) synthesis and produce downregulation
of DA-induced intracellular reactions of dephosphorylation
[272, 273]. Most of the D
2
-like presynaptic receptors are
autoreceptors, an exception is the D
2
-like somatodendritic
DA receptors [272–274]. These autoreceptors are located on
DA terminals and downregulation occurs due to inhibition of
DA synthesis and depolarization-induced release of DA from
terminals [275–278].
As specified above, the nigrostriatalDA system supervises
the activity of GABA and glutamatergic synapses of the dorsal
striatum (nucleus caudatus and putamen), which in turn
activate TC networks and regulate motor behavior in animals
and humans [279, 280]. Corticostriatal transmission is essen-
tial in the regulation of voluntary movement, in addition
to behavioural control. Long-term potentiation (LTP) and
long-term depression (LTD), the two main forms of synaptic
plasticity, are both represented at corticostriatal synapses
and strongly depend on the activation of DA receptors
[273]. The dorsal striatum is extremely homogeneous in
comparison with other cerebral areas. About 95% of dorsal
striatal neurons have the same morphology and are medium
spiny neurons, their function is to integrate all incoming
signals [272, 279, 281]. The medium spiny dorsal striatal neu-
rons receive excitatory glutamatergic synaptic information
through AMPA, kainite, and NMDA receptors practically
from all areas of the neocortex [272, 279]. The medium
spiny neurons are GABAergic; they use GABA as synaptic
transmitter. Consequently, postsynaptic inhibitory reactions
are carried out through postsynaptic GABAA receptors.
Postsynaptic GABAA receptors are located on dendrites and
the soma of the striatal medium spiny neurons, and also
on neurons of the globus pallidus, substantia nigra pars
reticulate, and thalamus [279].Themedium spiny neurons of
nucleus caudatus and putamen aremorphologically identical,
but differ neurochemically. One population contains GABA,
dynorphin, and substance P and primarily expresses Dl
receptors. These neurons send axons to GPi and to SNpr
(Figure 8) and form a direct pathway which inhibit GPi and
SNpr and are responsible for a reduction of an inhibitory
influence on TC inputs, thereby activating TC input neurons.
The second population contains GABA and enkephalin and
primarily expresses D
2
receptors. These neurons projects to
GPe and form a indirect pathway which inhibits TC input
(Figure 8). It is important to note that GABAergic terminals
form an indirect pathway that project to neurons of the RTN
[282]. That is, neurons of the RTN are controlled by D
2
receptors through GABAergic projections from the ventral
striatum.
In detail, an induction of intracellular signals DA by
receptors and control of GABAergic and glutamatergic
synaptic activity of medium spiny neurons of dorsal striatum
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has been described [272]. The DARPP-32/PP-1 (dopamine
and cyclic adenosine 3󸀠,5󸀠-monophosphate-regulated phos-
phoprotein, 32 kDa/phosphoprotein-1) pathway integrates
information from a variety of neurotransmitters and pro-
duces a coordinated response involving numerous down-
stream physiological effectors. DARPP-32 phosphorilation
at Thr-34 by PKA is regulated by the actions of various
neurotransmitters, principally DA acting at D
1
receptors,
but also adenosine acting at A
2A receptors and VIP acting
at VIP receptors. PKG is activated in response to NO,
also phosphorylates Thr-34 of DARPP-32. In medium spiny
neurons that coexpress D
1
and D
2
classes of DA receptors,
activation of D
2
receptors acts to decrease cAMP levels.
In medium spiny neurons that coexpress adenosine A
2A
receptors and D
2
receptors, activation of D
2
receptors also
acts to decrease cAMP levels. Opiates acting at either 𝜇 or
𝛿 receptors decrease cAMP levels in cells stimulated with
D
1
agonists or adenosine A
2A agonists, respectively. DARPP-
32 phosphorylated at Thr-34 is dephosphorylated by PP-2B,
a Ca2+/calmodulin-dependent protein phosphatase. PP-2B
activity is activated by a number of different neurotransmitter
receptors, principally following Ca2+ influx mediated by
glutamate acting at NMDA receptors. Glutamate acting at
AMPA receptors also stimulates DARPP-32 dephosphori-
lation by PP-2B, by an indirect mechanism that involves
depolarization of the neuron and influx of Ca2+. Activation
of D
2
receptors also leads to an increase in Ca2+ levels, via
an unidentified mechanism, and increased activity of PP-
2B. In contrast, GABA acting at GABAA receptors stimu-
lates DARPP-32 phosphorilation by hyperpolarization of the
neuron, decreased influx of Ca2+, and inactivation of PP-
2B. Neurotensin acts to increase DARPP-32 phosphorilation
by increasing the release of DA. CCK decreases DARPP-32
phosphorilation by increasing glutamatergic neurotransmis-
sion.The psychomotor stimulants cocaine and amphetamine
increaseDARPP-32 phosphorilation by increasingDAneuro-
transmission. All antipsychotic drugs achieve some of their
clinical effects via antagonism of the D
2
class of DA, an
action leading to an increase in the state of phosphorila-
tion of DARPP-32. Phospho-DARPP-32, by inhibiting the
activity of PP-1, acts in a synergistic manner with different
protein kinases to increase the level of phosphorilation of
various downstream effector proteins. The resulting increase
in phosphorilation is associated with increased activity of
NMDA and AMPA glutamate receptors, L-, N-, and P-type
Ca2+ channels, and early gene CREB and with decreased
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activity of GABAA receptors, Na
+ channels, and the Na+/K+-
ATPase. It is important to note from [272] scheme that
antagonists of the D
2
class of DA receptors increase GABAA
receptors activity, and agonists of the D
2
class of DA recep-
tors decrease GABAA receptors activity. Thus, intracellular
integrating transduction signal modifies all parameters of
neuronal activity. Modification of GABA and glutamate
ionotropic receptors activity will lead to updating of synaptic
neuronal inputs and outputs, defining participation of neuron
in functioning of a neural network. Modification of voltage-
dependent ionic channels activity modifies properties of
the electrogenic neural membrane. Integrating transduction
signal possesses the ability to modify not only the activity
of ionotropic, but also of metabotropic receptors of neurons
localized onmembranes and supervising transduction signal.
Such updating of all parameters of neurons, synaptic, electric,
and chemical, switches neurons to another functionally active
state or on other levels of functional activity. Depending on
the brain structure and of the modulatory system inducing
modification of transduction signal, a particular neuronal
state can be formed which can switch into another functional
state. For example, activation of the mesocorticolimbic DA
system of ventral tegmental area (Figure 7, A10) lateral
hypothalamus [283–285], nAcb [286, 287], prefrontal cortex
[288–291], and anterior cingulate cortex [292, 293], induces
an emotional positive state (pleasure and happiness [294–
297]), a state referring to its own prolongation and/or inten-
sification (intra-cranial-self-stimulation [283, 285, 286, 288,
290, 298], self-administration of drugs [290, 292, 299], self-
control of drug administration, or place-preference paradigm
[299–301]). Switching of neuron activity in other func-
tional state, through intracellular integration with the help
of transduction signal and modification of ionotropic and
metabotropic receptors and potential sensitive ionic channels
activity, it is possible to explain the role of the opioid
[285, 298], GABAergic [284, 287], acetylcholinergic [289],
serotoninergic [286, 287], and other systems in the control
of the mesocorticolimbic DAergic reinforcement system. We
define reinforcement as an emotional positive state arising as
a consequence of a reward and of an avoidance or escape of an
aversive stimulus, it induces purposeful motivated behavior.
As it has been shown above, one of the important
structures of the mesocorticolimbic DA system is the nAcb,
which is also called the ventral striatum [279]. The nAcb
consists of two groups of cells which differ anatomically: the
shell and core. Both parts of the ventral striatum participate
in emotionally positive reactions and in reinforcement. The
degree of participation of these two parts in reinforcement
(see above) depends on features of the experimental model
[302]. It is supposed that the core of the nAcb together
with the dorsal striatum participates in the realization and
control of purposeful behavior. The nigrostriatal DA system
participates in regulation of motor behavior by regulation of
TC neural networks (it is described in more details above).
The shell receives innervations from A10 DA cellular groups
(Figure 7), it is associated with the limbic system [268].
The nAcb core receives glutamatergic inputs from prefrontal
cortices (another important structure of reinforcement reac-
tion), thalamus, hippocampus, amygdala, and habenula.
Direct and indirect projections from the core of the nAcb
to the SNpr and VP in rats are described [303, 304]. Both
structures receive projections from the dorsal striatum.Thus,
the DA system of the ventral striatum (mesocorticolimbic)
cooperates with that of the dorsal striatum (nigrostriatal)
at the level of SNpr and VP which regulate TC networks
through the GABAergic system. It is necessary to add that
this interaction is supervised by the prefrontal cortex. It
is the structural basis for the realization of purposeful
motivated motor behavior, in particular when a choice for
the correct response can be made in order to get reinforced.
Behavioral experiments suggest that learning is driven by
changes in the expectations about future salient events such
as rewards and punishments. Physiological work has recently
complemented these studies by identifyingDAneurons in the
primate whose fluctuating output signals changes or errors
in the predictions of future salient and rewarding events
[305–307].
5.2. Features of WAG/Rij Rats Strain Related to the Function
of the DA System. It is known that SWDs are controlled by
the brain’s dopaminergic (DAergic) system. Antagonists of
D
2
DA receptors increase and agonists decrease of SWDs
[32, 304, 308–310].
The WAG/Rij rats can be regarded as a valid genetic
animal model of absence epilepsy with co morbidity of
depression [50–52]. Behavioral studies indicate thatWAG/Rij
rats exhibit depression-like symptoms: decreased explorative
activity in the open field test, increased immobility in the
forced swimming test, and decreased sucrose consumption
and preference (anhedonia). In addition,WAG/Rij rats adopt
passive strategies in stressful situations, express some cogni-
tive disturbances (reduced long-termmemory), helplessness,
and submissiveness, inability to make choices, and overcome
obstacles, which are typical for depressed patients. Elevated
anxiety is not a characteristic (specific) feature of WAG/Rij
rats; it is a characteristic for only a substrain of WAG/Rij
rats susceptible to audiogenic seizures [51]. Interestingly,
WAG/Rij rats display a hyperresponse to amphetamine
similar to anhedonic depressed patients. WAG/Rij rats are
sensitive only to chronic, but not acute, antidepressant
treatments, suggesting that WAG/Rij rats fulfill a criterion of
predictive validity for a putative animal model of depression.
However, more and different antidepressant drugs still await
evaluation. Depression-like behavioral symptoms in this
model are evident at baseline conditions, not exclusively after
exposure to stress. Experiments with foot-shock stress do
not point towards higher stress sensitivity at both behavioral
and hormonal levels. However, freezing behavior (coping
deficits) and blunted response of 5HT in the frontal cortex to
uncontrollable sound stress, increased c-fos expression in the
terminal regions of the mesocorticolimbic brain systems and
larger DA response of the mesolimbic system to forced swim
stress suggests that WAG/Rij rats are vulnerable to some, but
not to all types of stressors. In all, it seems that the depressive-
like behavior in WAG/Rij rats has a DA-dependent character
[311]. These results allow the assumption that the WAG/Rij
strain possesses a deficiency of the brain’s DA system activity.
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A low threshold for catalepsy, among others induced by
sound stress, was repeatedly found in WAG/Rij compared
to Wistar rats [308, 312]. WAG/Rij rats showed also both a
larger novelty and amphetamine induced increase in total
distancemoved than ACI rats in a brightly lit open field [310].
This novelty/amphetamine-induced ambulation score was
interpreted as an index of the reactivity of the DA system in
the mesolimbic system [313–315]. Index of the reactivity is in
addition bound, aswell as a catalepsy threshold, to a threshold
of sensitivity of a ligand-receptor interaction. It means that
the dissociation constant (𝐾d) of WAG/Rij rats DA receptors
is lower than in nonepileptic rats [316]. Unfortunately, there
are no data measuring the dissociation constant of DA
receptors.
It is possible to assume that control of SWDs by D
2
-like
DA receptors is carried out through an indirect GABAergic
pathway from the dorsal striatum which terminates in the
RTN through pathways passing through the GP (Figure 8),
one of the sources of rhythmic oscillations. Antagonists of
D
2
-like DA receptors enlarge activity of GABAA receptor
and increase SWD activity, and agonists reduce GABAA
receptor activity and reduce SWDs (see Section 3.1.1). D
2
-
like DA receptors in dorsal striatum induces phosphori-
lation of GABAA receptor and reduce its activity [272].
It has been shown that D
2
-like DA receptors selectively
block N-type Ca2+ channels to reduce GABA release onto
rat striatal cholinergic interneurons [317]. DA D
2
receptor-
mediated presynaptic inhibition of striatopallidal GABAA
IPSCs in vitro [318]. There were significant increases in
[
3H]nemonapride binding to D
2
-like receptors at different
time points due to treatment with haloperidol, chlorpro-
mazine, and olanzapine in rat striatum.By contrast, treatment
with clozapine and olanzapine caused a time-dependent
decrease in [3H]muscimol binding to the GABAA receptor of
striatum [319]. Dopamine D
4
receptor induced postsynaptic
inhibition of GABAergic currents in mouse GP neurons
[320]. An increase of GABAergic neurotransmission in the
striatum of mice lacking DA D
2
receptors was found [321].
The inhibitory effects of the DA D
2
receptor agonist quinpi-
role onGABAA-mediated spontaneous inhibitory postsynap-
tic currents correlate with the total number of D
2
receptor
sites in the striatum [322]. L-DOPA acting as D
2
-like agonist
inhibits GABA release in the rat globus pallidus and induces
turning behavior in rats with unilateral lesions of the DA
innervation [323]. Quinelorane, a dopamine D
3
/D
2
receptor
agonist, reduces prepulse inhibition of startle and GABA
efflux in the VP [324]. GABA release from pallidal terminals
in the STN nucleus and in the RTN is inhibited by activation
ofD
4
receptors [325]. Dopamine inhibits GABA transmission
from the GP to the RTN via presynaptic D
4
receptors [326,
327].
Thus, antagonists of D
2
-like DA receptors strengthen
GABA transmission into striatum, GP and RTN and raise
SWDs by promoting burst activity in the RTN, and agonists
operate in an opposite direction. Based on the electrophysio-
logical and lesion studies in WAG/Rij rats it is proposed that
there is no direct source of SWDactivity in theRTN, however,
bursting neurons in the RTN are a necessary condition for
maintenance and spreading of SWD [13, 20, 99].
5.2.1. The Processes of Defensive Learning and Memory
Controlled by DA System. An infringement of WAG/Rij
rat’s behavior was shown [51, 52, 328–331]. A decrease of
memory reproduction, spontaneous catalepsy, low threshold
of haloperidol-induced catalepsy, disturbances in maternal
behavior, and symptoms of depression-like behavior were
found in WAG/Rij rats. All these data can be explained
by a DA deficit on the WAG/Rij rat’s brain. The goal of
the investigation [332, 333] was to study the possibility
of WAG/Rij rat’s behavior correction by pharmacological
activation of DAergic system by disulfiram and L-3,4-
dihydroxyphenylalanine (L-DOPA, the precursor of DA syn-
thesis). Higher doses of disulfiram (100–300mg/kg) block the
efficiency of dopamine-𝛽-hydroxyls, the enzyme involved in
the synthesis of noradrenalin (NA) from DA. A lower dose
of 25mg/kg of disulfiram increases the DA content in the
brain without change of NA and transforms animals with an
emotional negative reaction to animals with an emotional
positive reaction in the emotional resonance behavioral
reaction test [334].
Rats were tested in a passive light avoidance and in a
classical two-way active avoidance task and the effects of this
dose of disulfiram on memory were investigated. The index
of memory trace storage (𝐼MT) was calculated as
𝐼MT =
𝐴
2
− 𝐴
1
𝐴
1
× 100%, (1)
where 𝐴
1
is the number of avoidance’s in learning session on
day 1, 𝐴
2
is the number of avoidance’s in the session on day 2
(both 50 trials).
There were three series of experiments. First series:
disulfiram was administered to Wistar and WAG/Rij rats of
the 1st group 4 hours before the 1st day learning session.
Second series: L-DOPA (also 25mg/kg i.p.) was administered
to Wistar and WAG/Rij rats of the 2nd group 4 hours before
the 1st learning session. In the 3rd series of experiment
disulfiram was administered immediately after 1st learning
session in Wistar and WAG/Rij rats. Control Wistar and
WAG/Rij rats received the same volume of saline.
Control WAG/Rij rats showed an amnesic reaction com-
pared to control Wistar rats at day 2 of the passive avoidance
conditioning procedure (Figures 9(a) and 9(b); in 2.65 and
3.89 times in (a) and (b), resp.). The administration of disul-
firam before as well as after passive avoidance conditioning
improved memory as measured the next day both in Wistar
andWAG/Rij rats, although the extent of increase was higher
inWAG/Rij than inWistar rats.The reproduction ofmemory,
as established in the passive avoidance test, was increased
1.34 and 1.41 times in Wistar rats and 4.21 and 4.89 times
in WAG/Rij rats accordingly. Administration of disulfiram
before learning did not change the latency to enter the
dark compartment in the first day nor induced a difference
between the strains later.
The administration of disulfiram4 hours before establish-
ment of active avoidance conditioning changed the learning
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Figure 9: The action of disulfiram in the reproduction of passive and active avoidance reflex on the next day by Wistar and WAG/Rij rats
strains. (a) is disulfiram (25mg/kg) administration 4 hours before learning of passive avoidance. (b) is disulfiram (25mg/kg) administration
immediately after learning of passive avoidance. x𝑃 < 0.05 versus to Wistar, ∗𝑃 < 0.05 versus to control, ∗∗𝑃 < 0.01 versus to control. (c)
is number of avoidances. (d) is index of memory trace storage. ∗𝑃 < 0.05 versus to Wistar control, x𝑃 < 0.05 versus to WAG/Rij control,
o
𝑃 < 0.05 versus to Wistar (Dis).
processes in the first day (Figure 9(c)). Control WAG/Rij
rats realized 2.23 times more avoidance responses than
control Wistar rats in the first day of learning (Figure 9(c)).
Disulfiram administration (DIS) before learning decreased
the number of avoidance responses in the first day: in Wistar
rats 1.47 times and in WAG/Rij rats 6.45 times (Figure 9(c)).
An amnesic effect in control WAG/Rij versus control Wistar
rats was found in the second day of learning: the memory
index of WAG/Rij rats was 2.11 times lower than in Wistar
rats (Figure 9(d)).The administration of disulfiram increased
memory index of Wistar rats 1.44 times and in WAG/Rij rats
7.33 times (Figure 9(d)).
The other inductor of DA system activation, L-DOPA,
was used for comparison. Synergic effects of disulfiram and
L-DOPA administered 4 hours before learning were found
(Figure 10). The administration of L-DOPA 4 hours before
learning decreased the number of avoidances in the first day
of learning in Wistar rats 1.76 times and in WAG/Rij rats
7.65 times (Figure 10(a)). Herewith, the index of memory
trace storage was increased in Wistar rats 1.82 times and in
WAG/Rij rats 7.70 times (Figure 8(b)).
A higher number of active avoidance responses in the
first day of learning and an amnesic effect in the second
day of learning in WAG/Rij versus Wistar rats (Figures
9(c), 10(a), and 10(c)) was reproduced three times in our
experiments. Administration of disulfiram immediately after
active avoidance conditioning in the first day significantly
increased the number of avoidance responses in the second
day; the reaction of WAG/Rij rats was more intense than in
Wistar rats (Figure 10(c)). In the memory trace storage the
relation Wistar (Dis) to Wistar is 1.8 and relation WAG/Rij
(Dis) to WAG/Rij is 2.48 (Figure 10(d)).
The amnesic effect in WAG/Rij versus Wistar rats in the
passive avoidance reflex was found earlier [328, 335]. The
amnesic effect can be explained by WAG/Rij rat’s epileptic
activity, the low efficiency of DA system and as a conse-
quence, a reduced sensitivity for reward (see above). The
improvement in the passive avoidance, (the dark was longer
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Figure 10: The action of administration of L-DOPA (25mg/kg) and disulfiram (Dis) (25mg/kg) on two days active avoidance conditioning
sessions for Wistar and WAG/Rij rats. (a) and (b) are L-DOPA administration 4 hours before learning of active avoidance, ∗𝑃 < 0.05 versus
Wistar control, x𝑃 < 0.05 versus WAG/Rij control, o𝑃 < 0.05 versus Wistar (L-DOPA). (c) and (d) of disulfiram administered immediately
after the first day learning of active avoidance, ∗𝑃 < 0.05 versus Wistar, ∗∗𝑃 < 0.05 versus WAG/Rij and to Wistar DIS x𝑃 < 0.05 versus
WAG/Rij control, o𝑃 < 0.05 versus Wistar (Dis).
avoided) in both WAG/Rij and Wistar rats after disulfiram
administration (Figure 7) can be explained by the same
processes, which is an agreement with the changes in the
emotional resonance behavioral reaction test [328]. It can
be supposed that a low dose of disulfiram before as well
as after learning increases the DA content in the brain,
increase the sensitivity for reward, and, as a consequence,
the consolidation process, the latter as expressed by a better
performance in the passive avoidance test the next day. It is
proposed here that the larger effects of disulfiram inWAG/Rij
rats reflect their deficit in theDA system. Besides, the increase
of DA system efficiency decreases in WAG/Rij rat’s amount
of epileptic activity [32, 304, 308, 309]. Activation of the DA
system can be considered as an anti-amnesic effect.
As it was specified above, the mesocorticolimbic DAergic
system is a reinforcement system, not a reward system. We
believe that there is a basic difference between reinforcement
and reward. Usually, as reward food, sweets and so on are
used. For some people one kind of food can be reward, and
for other people the same food can be aversive. Hence, the
relation to what is considered as reward is developed in the
history of an individual’s life. Usually reward, food and sweets
are given through the mouth. As in the somatosensory and
motor projections to dorsal striatum remains somatotopy
inherent to the cortex [279, 280] it is natural that the
reward involves nigrostriatal DA system [307, 336–340]. It
is necessary to notice that a subset of striatal neurons (10%)
is tonically active with discharge rates of 2 to 10Hz. These
neurons are distributed throughout the striatum and their
discharge bears no specific relation to movement. These
tonically active neurons (TANs) fire in relation to certain
sensory stimuli that are associated with reward. For example,
a TAN will fire in relation to a clicking sound if the click
precedes a fruit juice reward but will not fire to the click
alone or to the reward alone [279, 341]. It has been suggested
that these neurons signal aspects of tasks that are related
to learning and reinforcement. TANs are not activated by
electrical stimulation of the GP and thus are probably not
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projection neurons. It is thought that TANs are cholinergic
large aspiny interneurons that innervate the medium spiny
neurons (see earlier discussions), which would place them
in a position to modify the sensitivity of the medium spiny
neurons to cortical input in relation to specific behavioral
contexts [279].
We think that reinforcing properties of reward cause
emotionally positive states which induce emotionally positive
reactions, such as pleasure [342]. The purest kind of implica-
tion of the emotionally positive reaction refers to the prolon-
gation of the emotionally positive state is the reaction of self-
stimulation. Self-stimulation reaction can be observed only at
stimulation of the mesocorticolimbic DA systems [291, 343–
349], but not by stimulation of nigrostriatal DA systems.
But prolongation of emotionally positive state is motivation,
hence mesocorticolimbic DA system executes also function
of motivation [348, 350]. Thus, the mesocorticolimbic DA
system organizes behavior via modulation of emotional and
motivation states. In this case, it is conceivable that tonically
activated neurons of dorsal striatum play a complementary
role, due to their small numbers. It is possible that these
neurons are involved in the interaction processes of reinforce-
ment and reward. We consider that in our investigation the
avoidance of electrical current causes an emotionally positive
state and reinforces an avoidance reaction.The augmentation
of DA concentration in the brain by disulfiram or L-DOPA
strengthens the reaction to a reinforcer. Against the prospect
of a deficiency of DA and hyper reactivity of DA systems, the
investigated substances provoke much more intensive effect
in WAG/Rij than in Wistar rats.
The brain’s opioid system also controls SWDs. Different
agonists of kappa and antagonists of mu opioid receptors
decrease SWDs, and mu receptors agonists increase SWDs
[351–353]. It was also shown that a specific peptide of the
proenkephalin system was increased in the striatum, the
frontal cortex, and the mesencephalon [354, 355], structures
directly or indirectly controlling inhibitory processes in cor-
ticothalamocortical neuronal networks [21, 279, 280]. Also
from in situ hybridization studies, it appeared that the level
of the proenkephalin mRNAwas enhanced in the striatum of
WAG/Rij rats [356].
The opioid system controls the threshold of pain sensitiv-
ity and actualizes the motivation of escape and avoidance of
pain [299, 357, 358]. A high number of avoidance responses
were found earlier in WAG/Rij rats on the first day of active
avoidance conditioning (Figures 9 and 10) [328, 335]. We
explain this reaction by the low efficiency of opioid system
in WAG/Rij strain [351–356] and as a consequence a low
pain threshold and a high level of escape and avoidance
motivation. It has been shown [359–361] that activation
of the DAergic system evokes analgesic reaction including
activation of the opioid system [362–366]. It is important
that in the analgesic reaction of DAergic system the nAcb is
included [359, 360] and also that the interaction of DAergic
and opioid systems takes place in the striatum [272, 364], a
structure controlling SWDs. It is supposed that disulfiram
or L-DOPA administration before learning increases the
content of DA in the brain and via an enhancement of
the opioid system activity increases the pain threshold and
decreases pain avoidance motivation. At the same time DA-
induced reinforcement (modification of mesocorticolimbic
DA system) is increased, as well as memory consolidation
and memory reproduction on the next day (Figures 9 and
10). It has been shown (Kuznetsova, not published data) that
L-DOPA (25mg/kg) administration decreases SWDs activity
inWAG/Rij rats and that the same has been found for the DA
agonists apomorphine and cocaine [32, 367].
Disulfiram administration immediately after learning
increased DA-induced reinforcement (see above), increased
the process of memory consolidation, and increased active
avoidance memory reproduction on the next day (Figure 10).
It is possible that the larger effect in WAG/Rij rats is a
reflection of the DA and opioid systems efficiency deficit in
this strain of rats.
In all, a deficit of DA system in WAG/Rij rats and an
increase in the sensitivity to a DA agent as the response
on the deficit is proposed to be the causative factor for the
behavioural differences in Wistar and WAG/Rij rats.
A stablememory tracewas found in the passive avoidance
task in Wistar rats; however, WAG/Rijs performed less well.
Disulfiramadministration before and after learning increased
memory reproduction in this task in both strains of rats. The
enhancement of memory reproduction was more intense for
WAG/Rij than for Wistar rats. WAG/Rij rats realized more
correct avoidances than Wistar rats in the first day of active
avoidance learning. But in the next day of learning a memory
deficit was found inWAG/Rij rats. Lowdose of disulfiram and
L-DOPA administration before learning decreased learning
in the first day, but increased active avoidance memory
reproduction in the next day in both strains. This decrease
of learning and enhancement of memory was more intense
inWAG/Rij than inWistar rats. It was suggested that a deficit
of DA system in WAG/Rij rats is the biological correlate of
these behavioural deficits and that an enhanced sensitivity to
DAergic agents is the consequence of this deficit.
5.2.2. Measurement of DA Systems Activity in WAG/Rij Rats
Strain. Some parameters of DA activity inWAG/Rij rats were
studied in order to establish whether there was a deficiency.
DA synthesis and its degradation have been investigated in
70–80th of the last century in detail. It is well known that DA
is synthesized in DA terminals from tyrosine. The limitation
enzyme tyrosine-hydroxylase synthesizes L-DOPA (L-3,4-
dihydroxyphenylanine) from tyrosine. The second enzyme,
DOPA-decarboxylase, synthesizes DA from L-DOPA. DA
is taken up by vesicles of varicosity and stored there [368,
369]. During depolarization, DA is released into the inter-
cellular space and interacts with DA receptors. At this state
a higher concentration of released DA, receptors activity
and DA efficiency are observed. Further DA is retaken up
in terminals and glia cells by assistance of DA-transporter.
DA is inactivated by monoamine oxidase enzyme (MAO)
and through a number of enzymatic transformations turns
onto metabolite DOPAC (3,4-dihydroxyphenylacetic acid)
measured experimentally. By the help of another enzyme
of inactivationcatechol-O-methyltransferase (COMT) DA
passes through another enzymatic transformations and turns
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into the metabolite HVA (homovanillic acid) also measured
experimentally. The inhibition of the DA-transporter, MAO,
and COMT activity reduces an inactivation of DA, reduces
the concentration of DOPAC and HVA, raises the duration
of DA interaction with receptors, and enhances the efficiency
of the DA system [370–374].
The goal of our first experiment [375] was to investigate
DA and its metabolites, DOPAC and HVA concentration in
the following brain structures of Wistar and WAG/Rij rats:
frontal cortex, parietal cortex, medulla, striatum, thalamus,
and cerebellum. Concentrations of DA and its metabolites
have been defined by method of High Performance Liquid
Chromatography (HPLC). There was no difference in DA
concentration inWAG/Rij compared toWistar rats.However,
the concentrations ofmetabolites and theHVA/DAratiowere
substantially different in some structures between WAG/Rij
andWistar rats. DOPAC concentration was reduced in stria-
tum andHVA concentration in thalamus inWAG/Rij rats. As
noted above, one source of oscillations is located in thalamus
[19–22].The dorsal striatum is innervated by nigrostriatal DA
system controlling activity of TC networks and modulates
the occurrence of SWDs [21, 55, 279]. Reduction of the
concentration of metabolites in thalamus and striatum is
related to enhanced DA activity in these structures. The
strengthening of DA activity may occur as compensation for
DA deficiency at behavioural level.
The deficiency of DA activity is likely to be linked with
changes of DA receptors. In order to test such probability,
we compared [376, 377] D
1
and D
2
/D
3
DA receptors binding
sites with autoradiography in brain areas of WAG/Rij while
ACI rats were used as controls; the latter strain is nearly free
of SWDs [79].
Analyses of the optical densities of the autoradiograms
showed a significant reduction of [3H] SCH 23390 binding
sites (D
1
DA receptors) of WAG/Rij rats compared to ACI
rats in the shell of nAcb and in the head of caudate nucleus.
In other structures no significant changes were observed.The
results are presented in Table 1.
The results of [3H] spiperone binding for D
2
/D
3
DA
receptors are given in Table 2. An increase of these binding
sites was seen in WAG/Rij compared to ACI rats in motor,
somatosensory, and parietal cortex. The number of binding
sites was substantially lower than in the same structures
of ACI rat; in the head of caudate nucleus and in the
hippocampal CA3 area, a higher number was found inWAG/
Rij rats. No significant differences in these measures were
found in other structures.
Our results, a decrease of D
1
DA receptors number in
nAcb shell and in the head of caudate nucleus (Table 1), might
be related to a reduction of an upregulating effect of DAergic
transmission induced by phosphorilation.The increase in the
number of D
2
/D
3
DA receptors inmotor, somatosensory, and
parietal cortex was due to an amplification of downregulating
effect of DAergic transmission, induced by dephosphorila-
tion. The reduction of D
2
/D
3
DA receptors number in the
head caudate nucleus and in the CA3 area of hippocampus
(Table 2) corresponds to reduction of downregulating effect
Table 2: Density of [3H] spiperone binding sites in different brain
areas of ACI and WAG/Rij rats (D2/D3 receptors).
Brain regions ACI rats WAG/Rij rats 𝑃 < 0.05
Motor cortex 7.23 ± 0.52 9.8 ± 0.61 0.018
Somatosensory cortex 5.18 ± 0.32 8.19 ± 0.72 0.0052
Parietal cortex 6.41 ± 0.40 8.40 ± 0.78 0.0064
Nucleus accumbens (core) 16.15 ± 0.70 14.94 ± 1.25
Nucleus accumbens (shell) 22.79 ± 0.54 21.79 ± 1.22
Caudate nucleus (head) 25.89 ± 1.13 21.64 ± 0.47 0.0088
Caudate nucleus (ventral) 32.77 ± 1.09 36.33 ± 1.72
Caudate-putamen 30.15 ± 2.77 27.87 ± 2.46
CA3 area of hippocampus 2.80 ± 0.15 1.85 ± 0.30 0.024
of DAergic transmission, inducing the processes of dephos-
phorilation and enhancement of GABAA receptors activity.
The D
1
DA receptors are somatodendritic receptors; they
have not been found onDA terminals [378]. At the same time,
D
2
/D
3
DA receptors are both placed on soma and dendrites
of target cells, and on DA terminals [272, 274–278]. As
shown above, the autoreceptors modify DA release affecting
a synthesis measured by DA concentration in tissue samples.
In our previous study [375], we did not reveal significant
differences in DA concentration in various brain structures
of WAG/Rij compared to nonepileptic rats. It is possible that
changes of D
2
/D
3
DA receptors number revealed in this work
were mainly related with somatodendritic receptors.
The low number of somatodendric D
2
-like DA receptors
in the caudate nucleus induces endogenous processes of
dephosphorilation and enhancement of GABAA receptors
activity in striatum,GP, andRTN (Figure 8) and is an endoge-
nous cause for the increase of SWD activity in the corticotha-
lamocortical network. The high number of somatodendric
D
2
-like DA receptors in somatosensory cortex induce the
endogenous processes of phosphorilation and decrease of
GABAA receptors activity in somatosensory cortex, forming
an endogenous cause for decreasing SWDs in the cortical
focus, which supervises an oscillatory drive in the RTN
[20]. Possibly, it assumes compensatory reaction fromoutside
somatosensory cortex in relation to caudate nucleus. That is
why in WAG/Rij a compensated deficiency of D
2
-like DA
receptors is observed. But D
2
-like DA receptors antagonists’
administration both in cortex and caudate nucleus enhances
processes of dephosphorilation and GABAA receptors activ-
ity amplify, enlarging activity of SWDs.
A deficiency of mesolimbic (nAcb shell) DAergic activity
at the level of somatodendritic D
1
-like DA receptors in
WAG/Rij versus to ACI rats was found. At the same time
a deficiency of nigrostriatal DAergic system in the head of
caudate nucleus was caused by a reduction of D
1
-like and
D
2
-like DA receptors number. The deficiency of nigrostriatal
DAergic system by reduction of D
2
-like DA receptors is at the
bottom of an additional rising activity of SWDs. As D
1
-like
DA receptors supervise a direct pathway from striatumwhich
terminates on non epileptic nucleus of thalamus (Figure 8),
to us, there is no reason to assume that the deficiency D
1
-like
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DA receptors has an impact on the occurrence of activity of
SWDs.
The deficiency of mesocorticolimbic DA systems corre-
sponds to behavioral features of WAG/Rij rats. During active
and passive avoidance a deficit of reinforcement in WAG/Rij
rats has been revealed [332, 333] which was eliminated
by administration of the DA precursor, or a low dose of
disulfiram (Figures 9 and 10), inhibitor of dopamine-𝛽-
hydroxylase, by increase of DA concentration in brain [334].
Besides, it was shown thatWAG/Rij rats have a higher level of
depression than control Wistar rats without absence epilepsy
[50–52, 379]. Depression of WAG/Rij rats has a DAergic
nature [311] and can be explained by a deficiency of the DA
mesolimbic system. Behavioural changes and activity of the
mesolimbic DAergic systems in WAG/Rij rats are influenced
by activation of D
1
DA receptors in the shell of the nAcb
[380, 381] and prefrontal cortex [382, 383], the main sources
of positive reinforcement. D
2
-like DA receptors are also
involved in reinforcement [380, 381, 384, 385]. A link between
modification of behavior and alternative splicing of D
3
DA
receptor has been shown [386, 387]. The nAcb core [388]
and neostriatum [381] are not involved in reinforcement. It
is likely that D
1
- and D
2
-like DA receptors in the nAcb may
have more general influence on reinforced behavior [381].
The nigrostriatal DA system mediates behavioral reac-
tions through the control of TC neuronal networks.The nAcb
shell receives DAergic cellular innervations from the VTA;
this part of the nAcb is connected with limbic system [268,
279]. The nAcb core receives glutamatergic inputs from the
prefrontal cortex and thalamus, as well as from hippocampus
and amygdala. There are direct and indirect projections
from nAcb core to SNpr and VP in rats [304]. The pro-
jections from ventral striatum also pass to these structures.
Thus, interaction of mesocorticolimbic and striatonigral DA
systems at level of SNpr and VP controls thalamocortical
networks through GABAergic system, behavioral reactions,
and absence epileptic activity [21, 304].
Despite a compensated deficit of DA system of WAG/Rij
rats DA agonists and antagonists increase and decrease
SWDs, respectively [32]. Similar results were obtained in
the GAERS rats [389]. Intra-accumbal injections of DA
agonists and antagonists produced increase and decrease of
SWDs respectively [304]. Herewith the significant changes
in the nAcb (upregulation of mRNA D
3
DA receptor) were
revealed, although the levels of mRNA coding transporters
or enzyme of DA synthesis did not differ from controls [390].
The changes of DAergic system in nAcb core in GAERS
rats were slightly different than those received in WAG/Rij
rats at present work. But the general orientation of the
regulation of SWDs by DAergic in GAERS and WAG/Rij
rats was the same. Therefore it is possible to admit that the
mechanisms of DAergic regulation are also similar. It can be
that upregulation of mRNA D
3
DA receptor in the nAcb also
is a process of compensation.
Thus a deficiency in DA systems in WAG/Rij rats is
described and is mediated by D
1
- and D
2
-like DA receptors.
Reduction of D
1
-like DA receptors number in the shell
of the nAcb and in nucleus caudatus, reduction of D
2
-
like DA receptors number in nucleus caudatus and increase
of D
2
-like DA receptors number in motor, somatosensory,
and parietal cortex. Reduction of D
2
-like DA receptors
number in nucleus caudatus enhances the activity of GABAA
receptors in striatum, GP, and RTN, causing a rise in SWD-
activity in corticothalamocortical networks. High number
of somatodendric D
2
-like DA receptors in somatosensory
cortex inducing the endogenous processes of phosphorilation
and decrease of GABAA receptors activity in somatosensory
cortex, causing endogenous decrease of SWDs in cortical
focus, which supervises an oscillatory source in the RTN.We
assume that it reflects compensated deficiency of D
2
-like DA
receptors of WAG/Rij rats. Despite process of compensation
antagonists of D
2
-like DA receptors can raise activity GABAA
receptors both in a somatosensory cortex and in the RTN,
raising SWDs. Deficiency of WAG/Rij rats mesolimbic DA
systems, caused by reduction D
1
-like DA receptors in the
shell of the nAcb causes depression-like behavior of animals,
weakens formation of emotional positive state, worsens pro-
cesses of reinforcement, and counteracts learning and mem-
ory processes. Pharmacological intensification of DA systems
takes out negative reaction of deficiency of mesolimbic DA
system.
5.2.3. Possible Mechanisms of Infringement of DA System
Function in Absence Epilepsy. The question arises, if absence
epilepsy is related to disturbances or mutations of GABAA
receptor and low-threshold T-type Ca2+ channel, then what
is the role of DA receptors in it. Why is there a functional
deficiency of these receptors? We suggest two mechanisms
of infringement of the function of the DA system during
absence epilepsy.
(1) GABAA receptors mediate trophic effectson em-
bryonic brainstem monoamine neurons. GABA is
present in the mammalian brain during early stages
of development, where it may act as a trophic sig-
nal for developing neurons. In the embryonic rat,
GABA axons project through the brainstem when
5-HT, DA, and NA neurons are being generated
[391–394]. This raises the possibility that GABA
exert trophic influences on developing monoamine
neurons, if they express appropriate receptors. In
adult rat brain, these neurons do express functional
GABAA receptors [395–397]. The initial disruption
of GABAA receptor disrupts trophic influences on
developing monoamine neurons and induces patho-
logical changes in monoaminergic systems in adult
animals.
(2) Intraneuronal integration triggered by a transduction
signal.We believe that infringement of the function of
the DA system by intraneuronal integration triggered
by transduction signal occurs in the brain, especially
in structures in which there are no DA neurons, but
DA terminals, such as cortex, striatum, GP, thalamus,
nucleus nAcb, and so on.
5.2.4. Intraneuronal Integration Triggered by Transduction
Signal. Earlier it has been shown [165] that the develop-
ment of pentylenetetrazole (PTZ) kindling (4-month-old
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animals) is accompanied by 20% reduction of the density
(𝐵max) of GABAA receptor benzodiazepine (BDZ) sites. In
10-month animals, kindling reduced densities of the BDZ
site of GABAA receptor by 50%. Acute administration of a
subconvulsive dose of PTZ in the rats at 10 months of age
that were kindled at 4 month induces convulsive seizures
and densities of GABAA receptor BDZ site (𝐵max) to 20%
of control rats. The results suggest that the density of the
BDZ site at the GABAA receptors is reproduced at a level
of receptor molecule density independent of their current
status and age. The increased density of BDZ site of GABAA
receptors in kindled versus control rats can be interpreted
as an enhancement of GABAergic inhibition, while it is
thought that seizures are based on the process of neuronal
hyperactivation accompanied by a reduction in the BDZ
site density both in kindling-induced and single-dose PTZ-
induced seizures [165].Therefore, it is likely that at 10months,
when seizures are retrieved by a PTZ challenge and the level
of GABAergic inhibition is restored, the level of glutamate
receptors may also be restored, assuming that they were
modified and consolidated in the process of kindling 6
months ago. The level of glutamate receptors may only be
restored if neuronal GABA and glutamate receptors interact
within a single integrated system interconnected through an
intracellular transduction signal.
The interaction and integration of neuronal GABA and
glutamate receptors have been shown in several studies. A
reduction in GABAergic functions in PTZ-induced kindling
is blocked by MK-801, an antagonist of NMDA receptors
[162]. NMDA receptors are also involved in the process
of kindling induced by FG 7142, an inverse agonist of the
BDZ receptor [398]. Kindling produced by high-frequency
hippocampal stimulation induces an enhancement ofNMDA
receptors [399] as well as modification of GABAA receptors
[400]. Also, the NMDA-induced LTP is found to be con-
trolled by the intercellular metabolic systems of the GABAA
receptor complex, being inhibited by agonists acting at the
BDZ site [401, 402] and facilitated by its antagonists [403,
404]. Conversely, the NMDA antagonist CPP can modulate
the long-term modification (tolerance) of BDZ receptors
[405]. Positive allosteric activation of GABAA receptors bi-
directionally modulates hippocampal glutamate plasticity
and behavior [406]. Finally, BDZ withdrawal anxiety is asso-
ciated with potentiation of AMPA receptor currents in hip-
pocampal CA1 pyramidal neurons attributable to increased
synaptic incorporation of GluA1-containing AMPA receptors
[407].
The BDZ site is one of the metabolic sites of the GABAA
supramolecular receptor complex [408–412] which is subject
to long-term modifications [165, 400, 413]. The next of the
GABAA receptor metabolic site is the neuroactive steroids
site [116, 414]. LTP and LTD, like any long-term processes,
aremaintained bymodifications of gene expression [399, 400,
415–418]. BDZ site, acting via the second messengers system
and protein kinase C, can induce slow metabolic reactions in
the cell and modify gene expression in various structures of
rat brain [105, 408, 410, 419]. GABAA receptors are known to
be regulated by phosphorilation mediated by protein kinase
C and G [272, 273, 420–422]. Substrate for phosphorilation
and dephosphorilation of GABAA receptor is the intracellular
loop between the 3rd and 4th domain [204, 423, 424].
As indicated above, changes in cellular phosphorilation
levels by protein kinases can modify glutamatergic receptors
[162, 398, 399, 401–405], augmenting their responses to
endogenous excitatory amino acids. The prospective scheme
of this intracellular interaction is presented in Figure 11. The
metabolic regulation of glutamatergic synapses (Figure 11)
is described as a regulation of AMPA receptors by NMDA
receptors. Control of AMPA receptor by NMDA recep-
tor is described by plasticity in glutamatergic synapses of
hippocampus, striatum, and cortex [273, 425]. We added
a feedback loop for the regulation of AMPA receptors by
NMDA receptors as it is repeatedly described in studies
of the synthesis and trafficking of AMPA receptors subunit
to the plasmatic membrane [426–428]. The regulation of
AMPA receptors and autoregulation of NMDA receptors in
the hippocampus, striatum and cortex have been studied
experimentally [427, 429, 430].The autoregulation ofGABAA
receptors is also well described in investigations of synthesis
and trafficking of GABAA receptors subunit to the plasmatic
membrane [204, 431–433].
Thus, one can assume that plasticity is a result of coop-
erative activity of GABA and glutamatergic receptors inte-
grated into interrelated system. Integration includes also the
automodification of the activity or receptors. Furthermore,
a new level of activity, produced by secondary intranuclear
signals, modifies the gene expression and consolidates the
newly developed activity of receptors.
Functional interactions of the striatal glutamate and DA
receptors in learning and memory [279, 305, 306, 434, 435],
and postsynaptic integration of glutamatergic and DA signals
in the striatum based on interactions of intracellular second
messengers [272, 273, 279, 436–438] have been reported.The
D
4
receptor activation increases cofilin activity, causing a
decrease in the myosin-based transport of GABAA receptors
clusters to the surface in the prefrontal cortex [439]. It has
been shown [440] that the induction of LTDby low frequency
stimulation in hippocampal CA
1
neurons is under the influ-
ence of both NMDA and GABA receptors; both D
1
and D
2
receptors are involved in the modulation of LTD (activation
of D
1
receptors enhances LTD, activation of D
2
receptors
inhibits it) and the induction of LTD is blocked by picrotoxin,
this effect is superseded by D
1
receptors agonist SKF-38393.
Our results [441] also point to synergistic interactions of
GABAA and DA receptors in memory retrieval.
The intracellular integration by transduction signal of
glutamate, GABAA and DA receptors is schematically shown
in Figure 11. DA receptors can undergo automodification by
the metabolic feedback loop and then modify the activity
of glutamate and GABAA receptors by intracellular phos-
phorilation [272, 273]. Via the same reactions of intra-
cellular phosphorilation, glutamate and GABAA receptors
can control the efficiency of DA receptors. At the second
stage, the modifications established at the first stage are
consolidated through the modification of expression of the
respective genes. The ability of DA receptors to undergo
automodifications has been demonstrated both at the level
of radioligand binding and at the level of gene expression in
ISRN Neurology 31
GLU-R GABA(A) DA-R
PK
PK
PK
CaMK
PK
PKPK
DA-R subunits
GABA(A)
subunits
Glu-R
subunits
Nucleus
Ca2+
E SF SF SF G E
Fi
rs
t s
ta
ge
, s
ho
rt
-te
rm
Se
co
nd
 st
ag
e, 
lo
ng
-te
rm
Figure 11: A tentative model of intraneuronal integration triggered by transduction signal. GLU-R: glutamatergic receptors; GABA(A),
GABAA receptor; DA-R: dopamine receptor; E: second messenger synthesizing enzyme; SF: phosphorilation substrate; G: G-protein, PK:
different type of protein kinases; CaMK: calcium/calmodulin-dependent protein kinase. Metabolic reactions mediated by glutamatergic
receptors are shown as solid lines. Metabolic reactions mediated by GABAA receptor are shown as dashed lines. Metabolic reactions mediated
by dopamine receptors are shown as dotted lines. Intracellular metabolic feedback loops (autoregulation) are shown as the respective thick
lines. For other details, see text.
various brain structures and various experimental procedures
[319, 442–447].
We suggest that diminished activity of DA receptors and
DA system deficit occur due to disruption of intracellular
integration triggered by a transduction signal (Figure 11).
In the first place the initial disruption of GABAA receptor
activity disrupts the transduction signal from this receptor.
Disruption of transduction signal shapes the modification
of other receptors and their activity. In the second place
the disrupted activity of receptors is consolidated and stored
by expression of genes. It should be noted that we did
not see changes of DA concentrations in the structures
that we investigated, but we could see changes in receptor
activity and consequences of receptors activity. So, a process
of intracellular integration may disrupt activity of other
neurotransmitter and neuromodulatory systems, for instance
the activity of the opioid system that is disrupted inWAG/Rij
rats [351–356].
If the first possible mechanism of infringement of the
function of the DA system, mediation of trophic factor by
GABAA receptors, operates during a limited time period
corresponding to the period of embryonic development,
the second mechanism, intraneuronal integration triggered
by transduction signal, operates during the whole life and,
possibly, collects as a snow clot.
6. Conclusions
Thehyperpolarization-activated and cAMP-modulatedHCN
channels contribute to direct rhythmic activation in the brain.
Four isoforms of this channel are known: HCN1–HCN4.
HCN channels resemble voltage-dependent K+ channels;
they are tetrameric and consist of monomeric subunits, each
containing six transmembrane domains (S1–S6) with a P-
loop that forms a pore between the S5 and S6 domains.
Different HCN subunits may be connected and form a
heteromultimeric complex, thus significantly increasing the
diversity of 𝐼h channels. The HCN1 channel has a minimal
response to cAMP binding (+4mV) with a cAMP-binding
domain, whereas the HCN2 channel has a clear response
(+17mV). The coexpression of HCN1 and HCN2 with het-
eromultimeric channel formation leads to 𝐼h currents, which
tend to possess functional properties intermediate between
HCN1 and HCN2 homomeric channels. Experimental data
suggest that the 𝐼h channel and the low-threshold T-typeCa
2+
channel (𝐼Ca,T) work in tandem.Hyperpolarization opens the
𝐼h channel and a cationic current depolarizes the membrane
to the threshold and induces a spike. Hyperpolarization
also opens the (𝐼Ca,T) channel. The Ca
2+ ions that enter
the cell induce Ca2+-dependent cAMP synthesis and cAMP
dramatically increases channel activity through binding to
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the CNBD locus of HCN subunits. The HCN1 subunit
reacts weakly to cAMP binding; therefore, the decrease in
the proportion of HCN1 subunits in the channel increases
pacemaker activity and an increase in the proportion of
HCN1 subunits in the channel decreases pacemaker activity.
Analysis of the experimental data shows that one of the basic
mechanisms for the long-term regulation of 𝐼h pacemaker
activity is the modification of the number of HCN1 subunits
in the pacemaker channel. It has been assumed that the source
of SWDs is the 𝐼h pacemaker channel that is localized at pyra-
midal cells in the perioral region of the somatosensory cortex
(in WAG/Rij rats), more specifically layers III-VI. This part
of the cortex is fully integrated in a corticothalamocortical
circuit, which intactness is obligatory for the full expression
of the bilateral generalized SWDs. The RTN is part of this
circuitry, it has also pacemaker properties, and it generates
sleep spindles.
The density of a subtype of HCN channels (HCN1) in the
apical dendrites of the subgranular layers in this onset zone
determines the somatodendritic excitability and a decrease
of these dendritic HCN1 channels neurons increases the
occurrence of absences. Also in the thalamus HCN channels
are involved in burst firing typical for delta activity. Burst
firing of TC-cells is, however, rare during SWDs; it occurs
in only 7% of the TC cells although it cannot be excluded
that this a necessary condition for SWD occurrence. Burst
firing is caused by tandem hyperpolarization of 𝐼h and (𝐼Ca,T)
channels.
Pharmacological observations supported this point of
view since activation of GABAergic system through GABAA,
GABAB receptors and inhibition of GABA inactivation in the
synaptic cleft all leads to unequivocal result, intensification of
SWD activity. However, the measurements of the efficiency
of GABAergic system lead to diverse results. There might
be three reasons for this. First, different models of absence
epilepsy such as GAERS and WAG/Rij rats, various types of
mice with spontaneous mutations, and knock-out lines have
been used. It is possible that in these differentmodels, various
mechanisms of GABAergic system deficiency are present.
The second reason of occurrence of the variety of results is
the so-called process of uncertainty of the central nervous
system. The analysis of several works has shown that an
increase or decrease of the general activity of the transmission
system in different animals can be achieved in different ways
and depends on specific features of these animals. The third
reason of occurrence of diverse results can be processes of
indemnification. Strengthening of conductivity of chlorine
through GABAA receptors as found in WAG/Rij rats can be
considered as a compensation for the failure of inhibition of
GABAergic systems.
One of the reasons for the occurrence of absence epilepsy
is the mutation of several genes coding for GABAA receptors
which cause abnormal functioning of GABAergic system.
Such abnormal functioning of the GABAergic system and
mutations of (𝐼Ca,T) channel, which functions in tandemwith
𝐼h channel, can contribute to the occurrence of SWDs in the
EEG.
However, SWDs during absence epilepsy may also be
enhanced by the activation of the glutamate ionotropic and
metabotropic excitatory system. Agonists of three type’s
ionotropic excitatory glutamate receptors AMPA, kainate and
NMDA enhance SWDs; antagonists of these receptors reduce
SWDs. It is known from classical neurophysiology that
intensification of depolarization enlarges the frequency of
action potential discharges. The metabotropic glutamatergic
receptors also control SWDs, strengthening or controlling
them, dependent on their location within the corticothalam-
ocortical network. Various changes in number of receptors
were identified within the network. Indeed some mGluR’s
enhance SWDs, while mGlu1 and mGlu5 receptor agonists
and especially the positive allosteric modulators of Group
I receptors might be good candidates to control absence
seizures.
Deficiencies in DA systems in WAG/Rij rats were
revealed. They are mediated by D
1
- and D
2
-like DA recep-
tors. Reduction of the number of D
1
-like DA receptors in
the shell of the nucleus nAcb and in the nucleus caudatus,
and a reduction of D
2
-like DA receptors number in nucleus
caudatus and increase of D
2
-like DA receptors number in
motor, somatosensory, and parietal cortex. Reduction of D
2
-
like DA receptors number in nucleus caudatus causes an
enhancement of GABAA receptor activity in the striatum, GP,
and RTN; they are responsible for sleep spindle generation
and other rhythmic activity in TC networks. High number
of somatodendric D
2
-like DA receptors in somatosensory
cortex inducing the endogenous processes of phosphorilation
and decrease of GABAA receptors activity in somatosensory
cortex, causing endogenous decreasing of SWD activity in
the cortical focus, which might trigger and entrain thalamic
rhythmic firing and oscillations in the form of SWDs. We
assume that the enhanced D
2
-like DA receptors reflect a
compensated deficiency. Despite process of compensation,
antagonists of D
2
-like DA receptors can raise activity GABAA
receptors both in a somatosensory cortex and in the RTN,
raising SWDs. Deficiency of WAG/Rij rats mesolimbic DA
systems, caused by reduction D
1
-like DA receptors in the
shell of the nucleus nAcb, causes depression-like behavior
in animals, weakens the formation of emotional positive
state, worsens processes of reinforcement and counteracts
learning and memory processes. A pharmacological increase
of the DA system removes the negative consequences of the
deficiency of mesolimbic DA system.
The question arises, if absence epilepsy is due to distur-
bances or mutations of GABAA receptors and low-threshold
T-type Ca2+ channel what is the role of DA receptors in it.
Why is there a functional deficiency of these receptors? We
propose two mechanisms of infringement of the function of
the DA system during absence epilepsy.
(1) Intraneuronal integration is triggered by a trans-
duction signal. We believe that the infringement of
the function of the DA system by intraneuronal
integration triggered by transduction signal is carried
out in the brain, especially in structures inwhich there
are noDAneurons, butDA terminals are present such
as cortex, striatum, GP, thalamus, and nucleus nAcb.
We suggest that diminished activity of DA receptors and
DA system deficits occur due to disruption of intracellular
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integration triggered by a transduction signal.The initial dis-
ruption of GABAA receptor activity disrupts the transduction
signal of this receptor in the first stage. Disruption of the
transduction signal changes andmodifies other receptors and
their activity. On the second stage the disrupted activity of
receptors is consolidated and stored by the expression of
genes. It should be noted that we did not see changes of DA
concentrations in structures investigated, but we could see
the changes of receptors activity. So, a process of intracellular
integration may disrupt activity of other neurotransmitter
and neuromodulatory systems, for instance the activity of the
opioid system is disrupted in WAG/Rij rats.
(2) GABAA receptors mediate trophic effectson em-
bryonic brainstem monoamine neurons. GABA is
present in the mammalian brain during early stages
of development, where it may act as a trophic signal
for developing neurons. In the embryonic rat, GABA
axons project through the brainstemwhen 5-HT, DA,
and NA neurons are being generated. This raises the
possibility that GABA could exert trophic influences
on developing monoamine neurons, if they express
the appropriate receptors. In adult rat brain, these
neurons do express functional GABAA receptors.The
initial disruption of GABAA receptor disrupts the
trophic influences on developing monoamine neu-
rons and induces pathological changes inmonoamin-
ergic systems of adult animals.
The first possible mechanism, intraneuronal integration
triggered by transduction signal, operates during the whole
life and, possibly, collects as a snow clod. The second
mechanism, the infringement of the DA system’s function
on absence epilepsy and the mediation of trophic factor by
GABAA receptors, operates during a limited period of time
corresponding to the period of embryonic development.
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